timestamp,form_type,event_type,event_subtype,description,source_url,confidence
9/17/2024,8-K,sec_disclosure,corporate,"On September 15, 2024, the Company and Dr. Andrey Semechkin agreed to extend the maturity date of a $2,900,000 loan until September 15, 2025, repaid $200,000 of principal, and issued a new unsecured, non-convertible promissory note for the remaining $2,700,000 at 5.5% interest per annum.",https://www.sec.gov/Archives/edgar/data/1355790/000168316824006436/intlstemcell_8k.htm,0.9
9/17/2024,8-K,sec_disclosure,corporate,The amendment and replacement of the original promissory note gave rise to a new direct financial obligation under Item 2.03 of Form 8-K.,https://www.sec.gov/Archives/edgar/data/1355790/000168316824006436/intlstemcell_8k.htm,0.9
9/17/2024,8-K,sec_disclosure,regulatory,"The Company filed a Current Report on Form 8-K, including Exhibit 10.1 (the form of the new promissory note) and Exhibit 104 (Interactive Data File), to satisfy its SEC reporting requirements.",https://www.sec.gov/Archives/edgar/data/1355790/000168316824006436/intlstemcell_8k.htm,0.9
8/13/2024,10-Q,sec_disclosure,corporate,"Filed the Form 10-Q for the quarter ended June 30, 2024.",https://www.sec.gov/Archives/edgar/data/1355790/000095017024096128/isco-20240630.htm,0.9
8/13/2024,10-Q,sec_disclosure,corporate,"Issued unsecured non-convertible promissory notes on March 14, 2023 and September 15, 2023 as part of its financing activities.",https://www.sec.gov/Archives/edgar/data/1355790/000095017024096128/isco-20240630.htm,0.9
8/13/2024,10-Q,sec_disclosure,regulatory,"Adopted Accounting Standards Update 2020-06, updating its accounting for convertible instruments.",https://www.sec.gov/Archives/edgar/data/1355790/000095017024096128/isco-20240630.htm,0.9
8/13/2024,10-Q,sec_disclosure,regulatory,"Claimed Employee Retention Credits under the Coronavirus Aid, Relief, and Economic Security (CARES) Act for periods ending June 30, 2021 and December 31, 2021.",https://www.sec.gov/Archives/edgar/data/1355790/000095017024096128/isco-20240630.htm,0.9
5/14/2024,10-Q,sec_disclosure,regulatory,"International Stem Cell Corporation filed its Quarterly Report on Form 10-Q with the SEC for the period ended March 31, 2024, in compliance with the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000095017024059478/isco-20240331.htm,0.9
5/14/2024,10-Q,sec_disclosure,corporate,"International Stem Cell Corporation is incorporated in Delaware and maintains its principal executive offices in San Diego, California.",https://www.sec.gov/Archives/edgar/data/1355790/000095017024059478/isco-20240331.htm,0.9
11/13/2023,10-Q,sec_disclosure,regulatory,"The Company adopted Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (CECL), effective September 30, 2023.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023062890/isco-20230930.htm,0.9
11/13/2023,10-Q,sec_disclosure,corporate,"The Company identified and disclosed a subsequent event occurring on November 13, 2023, after the reporting period ended.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023062890/isco-20230930.htm,0.9
11/13/2023,10-Q,sec_disclosure,corporate,"The Company issued an unsecured, non-convertible promissory note on September 15, 2023.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023062890/isco-20230930.htm,0.9
11/13/2023,10-Q,sec_disclosure,corporate,"The Company issued an unsecured, non-convertible promissory note on September 15, 2022.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023062890/isco-20230930.htm,0.9
11/13/2023,10-Q,sec_disclosure,corporate,"The Company issued an unsecured, non-convertible promissory note on March 14, 2023.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023062890/isco-20230930.htm,0.9
11/13/2023,10-Q,sec_disclosure,regulatory,"The Company claimed the Employee Retention Credit under the Coronavirus Aid, Relief, and Economic Security (CARES) Act for the period March 12, 2020 through December 31, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023062890/isco-20230930.htm,0.9
11/13/2023,10-Q,sec_disclosure,regulatory,"The Company claimed the Employee Retention Credit under the Coronavirus Aid, Relief, and Economic Security (CARES) Act for the period January 1, 2021 through June 30, 2021.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023062890/isco-20230930.htm,0.9
9/18/2023,8-K,sec_disclosure,corporate,"On September 15, 2023, International Stem Cell Corporation and its Co-Chairman and CEO, Dr. Andrey Semechkin, agreed to extend the maturity date of a $2.9 million promissory note originally due September 15, 2023, by issuing a new unsecured, non-convertible note with a September 15, 2024 maturity and a 4.5% per annum interest rate.",https://www.sec.gov/Archives/edgar/data/1355790/000168316823006510/intlstemcell_8k.htm,0.9
6/21/2023,8-K,sec_disclosure,corporate,"International Stem Cell Corporation held its Annual Meeting of Stockholders on June 14, 2023.",https://www.sec.gov/Archives/edgar/data/1355790/000168316823004312/intl_8k.htm,0.9
6/21/2023,8-K,sec_disclosure,corporate,"At the Annual Meeting, holders of Series D Preferred Stock elected Andrey Semechkin and Russell Kern as directors to serve until the 2024 Annual Meeting.",https://www.sec.gov/Archives/edgar/data/1355790/000168316823004312/intl_8k.htm,0.9
6/21/2023,8-K,sec_disclosure,corporate,"At the Annual Meeting, holders of all shares of stock elected Donald A. Wright and Paul V. Maier as directors to serve until the 2024 Annual Meeting.",https://www.sec.gov/Archives/edgar/data/1355790/000168316823004312/intl_8k.htm,0.9
5/12/2023,10-Q,sec_disclosure,regulatory,"International Stem Cell Corporation filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000095017023021741/isco-20230331.htm,0.9
3/16/2023,8-K,sec_disclosure,corporate,"On March 15, 2023, the Company and its Co-Chairman and CEO, Dr. Andrey Semechkin, agreed to extend the maturity date of a $2.9 million promissory note originally due March 15, 2023, by issuing a new unsecured, non-convertible promissory note with a September 15, 2023 maturity date and a 4.5% annual interest rate, payable without penalty at any time.",https://www.sec.gov/Archives/edgar/data/1355790/000168316823001546/isco_8k.htm,0.9
9/16/2022,8-K,sec_disclosure,corporate,"On September 15, 2022, the Company and its Co-Chairman and CEO, Dr. Andrey Semechkin, agreed to extend the maturity date of a $2.9 million loan originally due on September 15, 2022, by issuing a new unsecured, non-convertible promissory note with a maturity date of March 15, 2023 and bearing interest at 4.5% per annum.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822006449/isco_8k.htm,0.9
9/16/2022,8-K,sec_disclosure,corporate,"In connection with the extension, the Company created a direct financial obligation under the new promissory note, which is due and payable on March 15, 2023 and may be prepaid without penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822006449/isco_8k.htm,0.9
9/16/2022,8-K,sec_disclosure,regulatory,"The Company filed a Current Report on Form 8-K on September 15, 2022, including Exhibit 10.1 (the form of the promissory note), in compliance with SEC disclosure requirements.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822006449/isco_8k.htm,0.9
8/12/2022,10-Q,sec_disclosure,regulatory,"The company performed a scenario forecast under Accounting Standards Update (ASU) 2021-04, reflecting the impact of that FASB update as of January 1, 2023.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022029273/isco-10q_20220630.htm,0.9
8/12/2022,10-Q,sec_disclosure,regulatory,"The company adopted Accounting Standards Update (ASU) 2021-10 effective June 30, 2022, reflecting new guidance issued by the FASB.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022029273/isco-10q_20220630.htm,0.9
8/12/2022,10-Q,sec_disclosure,corporate,"The company’s 2006 Equity Incentive Plan remains in effect, with outstanding awards and maximum share availability reviewed as of June 30, 2022.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022029273/isco-10q_20220630.htm,0.9
8/12/2022,10-Q,sec_disclosure,corporate,"The company’s 2010 Equity Incentive Plan remains in effect, with outstanding awards and maximum share availability reviewed as of June 30, 2022.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022029273/isco-10q_20220630.htm,0.9
6/14/2022,8-K,sec_disclosure,corporate,"International Stem Cell Corporation held its 2022 Annual Meeting of Stockholders on June 9, 2022, where holders of Series D Preferred Stock and common stock voting on an as-converted basis participated in corporate governance decisions.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822004317/isco_8k-061322.htm,0.9
6/14/2022,8-K,sec_disclosure,corporate,"Proposal 1 at the Annual Meeting: election of four directors (two by Series D Preferred Stock holders and two by all stockholders on an as-converted basis) to serve until the 2023 Annual Meeting, with Andrey Semechkin, Russell Kern, Donald A. Wright, and Paul V. Maier elected.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822004317/isco_8k-061322.htm,0.9
6/14/2022,8-K,sec_disclosure,corporate,"Proposal 2 at the Annual Meeting: an advisory (non-binding) vote on the compensation of the Company’s named executive officers, which passed with 7,544,159 votes in favor, 200,375 against, and 5,027 abstentions.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822004317/isco_8k-061322.htm,0.9
5/13/2022,10-Q,sec_disclosure,regulatory,"International Stem Cell Corporation filed its Quarterly Report on Form 10-Q with the SEC for the period ended March 31, 2022.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022020039/isco-10q_20220331.htm,0.9
5/13/2022,10-Q,sec_disclosure,regulatory,The registrant confirmed that it has electronically submitted all required Interactive Data Files under Rule 405 of Regulation S-T during the preceding 12 months.,https://www.sec.gov/Archives/edgar/data/1355790/000156459022020039/isco-10q_20220331.htm,0.9
5/13/2022,10-Q,sec_disclosure,regulatory,"The company disclosed subsequent events occurring on April 24 and April 25, 2022, after the quarter ended March 31, 2022.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022020039/isco-10q_20220331.htm,0.9
4/29/2022,8-K,sec_disclosure,corporate,"On April 25, 2022, International Stem Cell Corporation appointed Dr. Russell Kern as its principal financial officer, effective immediately.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822003021/isco-8k.htm,0.9
4/29/2022,8-K,sec_disclosure,corporate,"In connection with his appointment, the Company granted Dr. Kern options to purchase 1,000,000 shares of common stock.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822003021/isco-8k.htm,0.9
4/29/2022,8-K,sec_disclosure,corporate,"The Company also approved an increase in Dr. Kern’s annual salary to $130,000 per year.",https://www.sec.gov/Archives/edgar/data/1355790/000168316822003021/isco-8k.htm,0.9
3/3/2022,8-K,sec_disclosure,corporate,"On March 1, 2022, the Company and Dr. Andrey Semechkin agreed to extend the maturity date of a $2.9 million promissory note until September 15, 2022, and the Company issued an unsecured, non-convertible promissory note accruing interest at 4.5% per annum.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022008509/isco-8k_20220301.htm,0.9
3/3/2022,8-K,sec_disclosure,corporate,"The extension of the original promissory note created a direct financial obligation of $2.9 million under an off-balance sheet arrangement, as disclosed in Item 2.03.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022008509/isco-8k_20220301.htm,0.9
3/3/2022,8-K,sec_disclosure,regulatory,The Company filed Exhibit 10.1 (form of note) and Exhibit 104 (interactive data file) as part of its Current Report on Form 8-K.,https://www.sec.gov/Archives/edgar/data/1355790/000156459022008509/isco-8k_20220301.htm,0.9
2/2/2022,8-K,sec_disclosure,corporate,"On February 1, 2022, Sophia Garnette, the Company’s Principal Financial Officer and Vice President of Legal Affairs and Operations, submitted her resignation effective April 1, 2022, and will assist with the transition once her successor is identified.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022003423/isco-8k_20220201.htm,0.9
1/14/2022,8-K,sec_disclosure,corporate,"On January 13, 2022, the Company entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note in the principal amount of $2,900,000 to Dr. Andrey Semechkin, its Co-Chairman and CEO, to fund working capital needs.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022001352/isco-8k_20220113.htm,0.9
1/14/2022,8-K,sec_disclosure,corporate,"The issuance of the 2022 Promissory Note created a direct financial obligation for the Company—replacing the original $2,650,000 note with a new $2,900,000 note (including an additional $250,000), bearing 4.5% interest per annum, due March 15, 2022, and prepayable without penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022001352/isco-8k_20220113.htm,0.9
1/14/2022,8-K,sec_disclosure,regulatory,"The Company filed as Exhibit 10.1 to this Current Report on Form 8-K the form of the promissory note executed on January 13, 2022.",https://www.sec.gov/Archives/edgar/data/1355790/000156459022001352/isco-8k_20220113.htm,0.9
12/28/2021,8-K,sec_disclosure,corporate,"International Stem Cell Corporation entered into a Lease Termination Agreement with S Real Estate Holdings LLC to terminate its headquarters lease at 5950 Priestly Drive, Carlsbad, CA effective no later than December 31, 2021, including surrender of the premises, no termination fee, and release of December 2021 base rent obligations.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021061431/isco-8k_20211227.htm,0.9
11/1/2021,8-K,sec_disclosure,corporate,"On October 26, 2021, International Stem Cell Corporation and S Real Estate Holdings, LLC entered into a five-year and two-month lease agreement with Rehco Holdings for approximately 7,260 square feet of space at 9745 Businesspark Ave, San Diego, consolidating the Company’s Carlsbad and Oceanside offices.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021053192/isco-8k_20211026.htm,0.9
6/30/2021,8-K,sec_disclosure,corporate,"Holders of all remaining Series I-1 Preferred Stock converted their shares into common stock, resulting in no Series I-1 Preferred Stock outstanding.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021035333/isco-8k_20210625.htm,0.9
6/30/2021,8-K,sec_disclosure,corporate,"On June 25, 2021, the Company filed a Certificate of Elimination for the Series I-1 Preferred Stock with the state.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021035333/isco-8k_20210625.htm,0.9
6/30/2021,8-K,sec_disclosure,corporate,"The Certificate of Elimination amended the Company’s Certificate of Incorporation to eliminate the powers, designations, preferences, privileges, and other rights of the Series I-1 Preferred Stock.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021035333/isco-8k_20210625.htm,0.9
6/14/2021,8-K,sec_disclosure,corporate,"International Stem Cell Corporation held its Annual Meeting of Stockholders on June 9, 2021, at which holders considered one proposal described in the definitive proxy statement dated April 29, 2021.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021032797/isco-8k_20210609.htm,0.9
6/14/2021,8-K,sec_disclosure,corporate,"At the Annual Meeting, stockholders elected four directors—Andrey Semechkin and Russell Kern (elected by Series D Preferred Stock holders) and Donald A. Wright and Paul V. Maier (elected by all shares voting on an as-converted basis)—to hold office until the 2022 Annual Meeting.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021032797/isco-8k_20210609.htm,0.9
5/14/2021,10-Q,sec_disclosure,regulatory,"Filed its Quarterly Report on Form 10-Q with the SEC for the period ended March 31, 2021, affirming compliance with Section 13 or 15(d) of the Securities Exchange Act and Interactive Data requirements.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021027997/isco-10q_20210331.htm,0.9
5/14/2021,10-Q,sec_disclosure,corporate,"Experienced business disruptions due to the COVID-19 pandemic, leading to a year-over-year decline in product sales and prompting reductions in capital spending and operating expenses.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021027997/isco-10q_20210331.htm,0.9
5/14/2021,10-Q,sec_disclosure,clinical,"Cyto Therapeutics Pty. Ltd., a wholly-owned subsidiary, is conducting clinical trials in Australia of ISC-hpNSC cells for the treatment of Parkinson’s disease.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021027997/isco-10q_20210331.htm,0.9
5/14/2021,10-Q,sec_disclosure,corporate,"Received $474,000 in proceeds under the U.S. Paycheck Protection Program loan during the quarter ended March 31, 2021 to support its operations.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021027997/isco-10q_20210331.htm,0.9
5/14/2021,10-Q,sec_disclosure,corporate,"Entered into a related party note payable, raising $350,000 during the three months ended March 31, 2021.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021027997/isco-10q_20210331.htm,0.9
5/14/2021,10-Q,sec_disclosure,ip,"Incurred and accrued costs for patent licenses, reflecting payments for IP rights during the quarter.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021027997/isco-10q_20210331.htm,0.9
3/8/2021,8-K,sec_disclosure,corporate,"On January 15, 2021, the Company amended its original December 17, 2019 promissory note by extending the maturity date to January 15, 2022.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021011478/isco-8k_20210305.htm,0.9
3/8/2021,8-K,sec_disclosure,corporate,"On March 5, 2021, International Stem Cell Corporation issued an unsecured, non-convertible promissory note in the principal amount of $2,650,000 to Dr. Andrey Semechkin, who provided an additional $350,000 in funding and surrendered the amended original note in exchange.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021011478/isco-8k_20210305.htm,0.9
3/8/2021,8-K,sec_disclosure,regulatory,"The Company filed the form of the March 5, 2021 promissory note as Exhibit 10.1 to its Form 8-K current report.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021011478/isco-8k_20210305.htm,0.9
1/19/2021,8-K,sec_disclosure,corporate,"On January 15, 2021, the Company and its Co-Chairman and CEO, Dr. Andrey Semechkin, agreed to extend the maturity date of a $2.3 million promissory note from January 15, 2021 to January 15, 2022 and issued a new unsecured, non-convertible promissory note at 4.5% interest per annum.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021001473/isco-8k_20210115.htm,0.9
1/19/2021,8-K,sec_disclosure,corporate,"Pursuant to Item 2.03, the issuance of the new promissory note constitutes the creation of a direct financial obligation of the Company in the amount of $2.3 million, payable on January 15, 2022 with no prepayment penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021001473/isco-8k_20210115.htm,0.9
1/19/2021,8-K,sec_disclosure,regulatory,"As required by Item 9.01, the Company filed as Exhibit 10.1 to the Form 8-K the full form of the promissory note issued on January 15, 2021.",https://www.sec.gov/Archives/edgar/data/1355790/000156459021001473/isco-8k_20210115.htm,0.9
11/12/2020,10-Q,sec_disclosure,corporate,"International Stem Cell Corporation received a Paycheck Protection Program loan of $654,000 during the nine months ended September 30, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020053534/isco-10q_20200930.htm,0.9
11/12/2020,10-Q,sec_disclosure,ip,"The Company paid $58,000 for patent licenses during the nine months ended September 30, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020053534/isco-10q_20200930.htm,0.9
11/12/2020,10-Q,sec_disclosure,corporate,"An impairment charge of $65,000 on intangible assets was recorded during the nine months ended September 30, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020053534/isco-10q_20200930.htm,0.9
11/12/2020,10-Q,sec_disclosure,corporate,"A related‐party bridge loan of $1,049,000 was converted into common stock during the nine months ended September 30, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020053534/isco-10q_20200930.htm,0.9
11/12/2020,10-Q,sec_disclosure,corporate,"Stock-based compensation expense totaling $1,015,000 was recognized during the nine months ended September 30, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020053534/isco-10q_20200930.htm,0.9
11/12/2020,10-Q,sec_disclosure,corporate,"The fair value of the warrant liability changed by $167,000 (favorable) for the nine months ended September 30, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020053534/isco-10q_20200930.htm,0.9
11/12/2020,10-Q,sec_disclosure,corporate,"Property and equipment purchases totaling $24,000 were made during the nine months ended September 30, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020053534/isco-10q_20200930.htm,0.9
6/29/2020,8-K,sec_disclosure,corporate,"International Stem Cell Corporation held its Annual Meeting of Stockholders on June 23, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000119312520182621/d63146d8k.htm,0.9
6/29/2020,8-K,sec_disclosure,corporate,"Stockholders elected four directors—Andrey Semechkin, Russell Kern, Donald A. Wright, and Paul V. Maier—to hold office until the 2021 Annual Meeting.",https://www.sec.gov/Archives/edgar/data/1355790/000119312520182621/d63146d8k.htm,0.9
6/29/2020,8-K,sec_disclosure,corporate,Stockholders approved an amendment to the 2010 Equity Participation Plan.,https://www.sec.gov/Archives/edgar/data/1355790/000119312520182621/d63146d8k.htm,0.9
6/1/2020,10-K,sec_disclosure,regulatory,"The Company delayed filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 due to disruptions caused by the COVID-19 pandemic, missing its original March 30, 2020 deadline.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020027718/isco-10k_20191231.htm,0.9
6/1/2020,10-K,sec_disclosure,regulatory,"On March 30, 2020, the Company filed a Form 8-K with the SEC to disclose the delay in its 2019 Annual Report and the impact of the COVID-19 outbreak on its operations.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020027718/isco-10k_20191231.htm,0.9
6/1/2020,10-K,sec_disclosure,regulatory,"The Company relied on the SEC’s Order Under Section 36 of the Securities Exchange Act of 1934 (Release Nos. 34-88318 and 34-88465) issued on March 4 and amended March 25, 2020, to delay filing its 2019 Annual Report.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020027718/isco-10k_20191231.htm,0.9
6/1/2020,10-K,sec_disclosure,corporate,"In response to the COVID-19 pandemic, the Company implemented precautionary measures including encouraging employees to work from home, suspending all non-essential travel, discouraging in-person meetings, and identifying expense reductions for the remainder of fiscal 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020027718/isco-10k_20191231.htm,0.9
6/1/2020,10-K,sec_disclosure,corporate,"The Company’s laboratories in Frederick, Maryland and Oceanside, California continued operations during the pandemic but remain under evaluation and could be temporarily shut down if conditions worsen.",https://www.sec.gov/Archives/edgar/data/1355790/000156459020027718/isco-10k_20191231.htm,0.9
5/13/2020,8-K,sec_disclosure,regulatory,"The SEC issued an order (Release No. 34-88465) on March 25, 2020 under Section 36 of the Securities Exchange Act of 1934 that allows affected registrants up to a 45-day extension for filing specified reports due to COVID-19 disruptions.",https://www.sec.gov/Archives/edgar/data/1355790/000119312520141404/d930412d8k.htm,0.9
5/13/2020,8-K,sec_disclosure,corporate,"International Stem Cell Corporation furnished a Current Report on Form 8-K on May 13, 2020 to notify the SEC and investors that it is relying on the SEC’s order to delay filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000119312520141404/d930412d8k.htm,0.9
5/13/2020,8-K,sec_disclosure,corporate,"The Company announced its plan to file the delayed Quarterly Report on Form 10-Q by no later than June 29, 2020, which is 45 days after the original May 15, 2020 due date.",https://www.sec.gov/Archives/edgar/data/1355790/000119312520141404/d930412d8k.htm,0.9
12/19/2019,8-K,sec_disclosure,corporate,"On December 17, 2019, the Company issued an unsecured, non-convertible promissory note for $2.3 million to Dr. Andrey Semechkin (its Co-Chairman and CEO)—including a $500,000 extension of an existing note—in exchange for the original $1.8 million note. The note accrues interest at 4.5% per annum, is payable on January 15, 2021, and may be prepaid without penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519318940/d853494d8k.htm,0.9
12/19/2019,8-K,sec_disclosure,corporate,"The issuance of the December 17, 2019 promissory note constituted the creation of a direct financial obligation of the Company under Item 2.03 of Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519318940/d853494d8k.htm,0.9
11/12/2019,10-Q,sec_disclosure,corporate,"The Company recorded an out-of-period correction in its Q1 2019 financial statements, resulting in a $8.8 million decrease in additional paid-in capital and a net $4.3 million adjustment to accumulated deficit and preferred stock balances.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019042862/isco-10q_20190930.htm,0.9
11/12/2019,10-Q,sec_disclosure,corporate,"During Q1 2019 the Company converted $1.05 million of debt into 599,000 shares of common stock, increasing additional paid-in capital by $1.048 million.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019042862/isco-10q_20190930.htm,0.9
11/12/2019,10-Q,sec_disclosure,corporate,"The Company recognized stock-based compensation expense totaling $1.589 million during the nine months ended September 30, 2019 (comprising $506 k in Q1, $571 k in Q2 and $512 k in Q3).",https://www.sec.gov/Archives/edgar/data/1355790/000156459019042862/isco-10q_20190930.htm,0.9
11/12/2019,10-Q,sec_disclosure,corporate,"Upon adoption of the new lease accounting standard (ASC 842), the Company recorded $784 k of right-of-use assets and $1.165 million of operating lease liabilities (current and non-current) as of September 30, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019042862/isco-10q_20190930.htm,0.9
8/27/2019,10-Q,sec_disclosure,corporate,"International Stem Cell Corporation filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019033042/isco-10q_20190630.htm,0.9
8/27/2019,10-Q,sec_disclosure,regulatory,The registrant submitted every required Interactive Data File electronically pursuant to Rule 405 of Regulation S-T during the preceding 12 months.,https://www.sec.gov/Archives/edgar/data/1355790/000156459019033042/isco-10q_20190630.htm,0.9
8/27/2019,10-Q,sec_disclosure,corporate,International Stem Cell Corporation is classified as a non-accelerated filer and a smaller reporting company under SEC rules.,https://www.sec.gov/Archives/edgar/data/1355790/000156459019033042/isco-10q_20190630.htm,0.9
8/27/2019,10-Q,sec_disclosure,corporate,"Upon adoption of the new lease accounting standard, the company recognized a right-of-use asset of $849,000 and corresponding operating lease liabilities.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019033042/isco-10q_20190630.htm,0.9
8/27/2019,10-Q,sec_disclosure,corporate,An out-of-period correction was made to adjust the carrying amount of Series D Redeemable Convertible Preferred Stock.,https://www.sec.gov/Archives/edgar/data/1355790/000156459019033042/isco-10q_20190630.htm,0.9
8/27/2019,10-Q,sec_disclosure,corporate,"Debt was converted into common stock, resulting in the issuance of 599,222 shares and an increase in additional paid-in capital.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019033042/isco-10q_20190630.htm,0.9
7/30/2019,8-K,sec_disclosure,corporate,"On July 25, 2019, the Audit Committee concluded the Company’s eight-year engagement with Mayer Hoffman McCann P.C. as its independent registered public accounting firm.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519206987/d784689d8k.htm,0.9
7/30/2019,8-K,sec_disclosure,corporate,"On July 25, 2019, the Audit Committee approved the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519206987/d784689d8k.htm,0.9
7/30/2019,8-K,sec_disclosure,regulatory,"As of December 31, 2017 and December 31, 2018, the Company reported material weaknesses in its internal control over financial reporting related to equity transactions, financial reporting, technical accounting, and adoption of new standards.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519206987/d784689d8k.htm,0.9
7/30/2019,8-K,sec_disclosure,corporate,"The Company authorized Mayer Hoffman McCann P.C. to respond fully and without limitation to any inquiries from BDO USA, LLP regarding the identified material weaknesses.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519206987/d784689d8k.htm,0.9
7/30/2019,8-K,sec_disclosure,regulatory,"On July 26, 2019, Mayer Hoffman McCann P.C. furnished a letter to the SEC, filed as Exhibit 16.1, stating its agreement or disagreement with the Form 8-K disclosures.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519206987/d784689d8k.htm,0.9
6/7/2019,8-K,sec_disclosure,corporate,"International Stem Cell Corporation held its Annual Meeting of Stockholders on June 3, 2019, at which shareholders considered three proposals described in the definitive proxy statement dated April 30, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519168056/d712164d8k.htm,0.9
6/7/2019,8-K,sec_disclosure,corporate,Proposal 1: Shareholders elected four directors—two by holders of Series D Preferred Stock and two by holders of all shares of stock—to serve until the 2020 Annual Meeting.,https://www.sec.gov/Archives/edgar/data/1355790/000119312519168056/d712164d8k.htm,0.9
6/7/2019,8-K,sec_disclosure,corporate,"Proposal 2: Shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519168056/d712164d8k.htm,0.9
6/7/2019,8-K,sec_disclosure,corporate,"Proposal 3: Shareholders voted, on an advisory basis, to hold future advisory votes on executive compensation every three years, and the Board determined to adopt a three-year frequency.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519168056/d712164d8k.htm,0.9
6/7/2019,8-K,sec_disclosure,regulatory,"The Company filed a Current Report on Form 8-K on June 7, 2019, under Item 5.07 to report the submission of matters to a vote of security holders.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519168056/d712164d8k.htm,0.9
5/15/2019,10-Q,sec_disclosure,corporate,"Filed the Quarterly Report on Form 10-Q with the SEC for the period ended March 31, 2019, including unaudited condensed consolidated financial statements and related disclosures.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019019386/isco-10q_20190331.htm,0.9
5/15/2019,10-Q,sec_disclosure,corporate,"Converted a bridge loan from a related party totaling $1,049,000 into common stock during the three months ended March 31, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019019386/isco-10q_20190331.htm,0.9
5/15/2019,10-Q,sec_disclosure,corporate,"Issued common stock for services and upon exercise of stock options, including conversion of certain debt instruments into equity.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019019386/isco-10q_20190331.htm,0.9
5/15/2019,10-Q,sec_disclosure,regulatory,"Recognized a right-of-use asset of $933,000 and corresponding lease liabilities upon adoption of new lease accounting standards in the period ended March 31, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019019386/isco-10q_20190331.htm,0.9
5/15/2019,10-Q,sec_disclosure,ip,"Paid $61,000 for patent licenses and trademark registrations during the three months ended March 31, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019019386/isco-10q_20190331.htm,0.9
5/15/2019,10-Q,sec_disclosure,ip,"Recorded an impairment charge of $111,000 on intangible assets during the three months ended March 31, 2018.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019019386/isco-10q_20190331.htm,0.9
5/15/2019,10-Q,sec_disclosure,corporate,"Obtained a $350,000 bridge loan from a related party in the first quarter of 2018 to fund operations.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019019386/isco-10q_20190331.htm,0.9
4/23/2019,8-K,sec_disclosure,corporate,"On April 17, 2019, the Company issued an unsecured, non-convertible promissory note in the principal amount of $1,800,000 to Dr. Andrey Semechkin to obtain funding for working capital.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519115027/d737100d8k.htm,0.9
4/23/2019,8-K,sec_disclosure,corporate,"On January 21, 2019, the Company issued an original promissory note in the principal amount of $1,000,000 to Dr. Andrey Semechkin, which was later surrendered in connection with the new April 17, 2019 note.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519115027/d737100d8k.htm,0.9
4/23/2019,8-K,sec_disclosure,regulatory,"The Company filed the form of Note issued on April 17, 2019 as Exhibit 10.1 to its Current Report on Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519115027/d737100d8k.htm,0.9
4/15/2019,10-K,sec_disclosure,corporate,"Filed the Annual Report on Form 10-K for the fiscal year ended December 31, 2018.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019011540/isco-10k_20181231.htm,0.9
4/15/2019,10-K,sec_disclosure,regulatory,Completed IND-enabling preclinical studies for the ISC-hpNSC neural stem cell therapy program targeting Parkinson’s disease.,https://www.sec.gov/Archives/edgar/data/1355790/000156459019011540/isco-10k_20181231.htm,0.9
4/15/2019,10-K,sec_disclosure,regulatory,Submitted a regulatory application to the Australian Therapeutics Goods Administration (TGA) for the ISC-hpNSC clinical program.,https://www.sec.gov/Archives/edgar/data/1355790/000156459019011540/isco-10k_20181231.htm,0.9
4/15/2019,10-K,sec_disclosure,clinical,Commenced a Phase I clinical trial in Australia evaluating ISC-hpNSC transplantation in patients with Parkinson’s disease.,https://www.sec.gov/Archives/edgar/data/1355790/000156459019011540/isco-10k_20181231.htm,0.9
4/15/2019,10-K,sec_disclosure,clinical,Successfully transplanted ISC-hpNSC neural stem cells into 11 Parkinson’s disease patients as of March 2019.,https://www.sec.gov/Archives/edgar/data/1355790/000156459019011540/isco-10k_20181231.htm,0.9
4/15/2019,10-K,sec_disclosure,ip,"Developed the first parthenogenetic, homozygous human stem cell line (hpSC) enabling the potential for immune-matched therapeutic cells.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019011540/isco-10k_20181231.htm,0.9
4/15/2019,10-K,sec_disclosure,corporate,"Generated $11.1 million and $7.5 million in revenue from cosmetic and research product sales in 2018 and 2017, respectively.",https://www.sec.gov/Archives/edgar/data/1355790/000156459019011540/isco-10k_20181231.htm,0.9
1/23/2019,8-K,sec_disclosure,corporate,"On January 21, 2019, the Company entered into a Note Conversion Agreement with its CEO, converting $1,048,638.89 of principal and accrued interest under an existing promissory note into 599,222 shares of common stock at $1.75 per share and replacing the remaining $1,000,000 principal with a new unsecured, non-convertible promissory note due January 15, 2020 at 4.5% interest.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519014844/d653869d8k.htm,0.9
1/23/2019,8-K,sec_disclosure,regulatory,"On November 15, 2018, the Company issued 150,000 shares of common stock to holders of Series I-1 Convertible Preferred Stock upon conversion of a portion of their preferred shares at a conversion price of $1.75 per share, relying on the Section 3(a)(9) exemption from registration under the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519014844/d653869d8k.htm,0.9
1/23/2019,8-K,sec_disclosure,regulatory,"On January 21, 2019, the Company issued 599,222 shares of common stock in a private transaction upon conversion of outstanding indebtedness and accrued interest, relying on the Section 4(a)(2) exemption from registration under the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312519014844/d653869d8k.htm,0.9
11/15/2018,8-K,sec_disclosure,corporate,"On November 12, 2018, International Stem Cell Corporation entered into a First Amendment to Promissory Note with its Co-Chairman and CEO, Dr. Andrey Semechkin, amending the original August 8, 2018 note to extend its maturity date from November 1, 2018 to January 15, 2019.",https://www.sec.gov/Archives/edgar/data/1355790/000119312518326978/d649761d8k.htm,0.9
11/15/2018,8-K,sec_disclosure,regulatory,"The Company filed the First Amendment to Promissory Note, dated November 12, 2018, as Exhibit 10.1 to its Current Report on Form 8-K with the Securities and Exchange Commission.",https://www.sec.gov/Archives/edgar/data/1355790/000119312518326978/d649761d8k.htm,0.9
10/3/2018,8-K,sec_disclosure,corporate,"On August 14, 2018, the Company filed its Quarterly Report on Form 10-Q for the period ended June 30, 2018, reporting 6,299,821 shares outstanding as of August 13, 2018.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018023907/isco-8k_20181003.htm,0.9
10/3/2018,8-K,sec_disclosure,corporate,"Through September 27, 2018, the Company issued an additional 445,906 shares of common stock, representing an increase of over 5% in outstanding shares compared to the number reported in the Quarterly Report.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018023907/isco-8k_20181003.htm,0.9
10/3/2018,8-K,sec_disclosure,corporate,"On September 21, 2018, the Company issued 285,714 shares to an accredited investor at $1.75 per share for total proceeds of $500,000.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018023907/isco-8k_20181003.htm,0.9
10/3/2018,8-K,sec_disclosure,corporate,"On September 27, 2018, the Company issued 160,192 shares to a trade creditor in satisfaction of $280,337 owed, at $1.75 per share.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018023907/isco-8k_20181003.htm,0.9
10/3/2018,8-K,sec_disclosure,regulatory,The shares issued in these transactions were private placements made in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933.,https://www.sec.gov/Archives/edgar/data/1355790/000156459018023907/isco-8k_20181003.htm,0.9
10/3/2018,8-K,sec_disclosure,regulatory,"On October 3, 2018, the Company filed a Form 8-K current report with the SEC to disclose the unregistered sales of equity securities.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018023907/isco-8k_20181003.htm,0.9
6/27/2018,8-K,sec_disclosure,corporate,"The Company held its Annual Meeting of Stockholders on June 21, 2018, at which stockholders considered and voted on corporate proposals.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018016290/isco-8k_20180627.htm,0.9
6/27/2018,8-K,sec_disclosure,corporate,Stockholders elected four directors—two by Series D Preferred Stock holders and two by all shareholders—to hold office until the 2019 Annual Meeting.,https://www.sec.gov/Archives/edgar/data/1355790/000156459018016290/isco-8k_20180627.htm,0.9
6/27/2018,8-K,sec_disclosure,corporate,"Stockholders approved amendments to the Company’s 2010 Equity Participation Plan, as presented in the definitive proxy statement.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018016290/isco-8k_20180627.htm,0.9
6/5/2018,8-K,sec_disclosure,corporate,"On May 31, 2018, the Company issued an unsecured, non-convertible promissory note in the principal amount of $1,100,000 to its Co-Chairman and CEO, Dr. Andrey Semechkin, bearing 4% annual interest and due November 1, 2018 with prepayment allowed without penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018015020/isco-8k_20180531.htm,0.9
6/5/2018,8-K,sec_disclosure,corporate,"On March 14, 2018, the Company previously issued an $800,000 promissory note to Dr. Andrey Semechkin, which was later surrendered in connection with the May 31, 2018 note.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018015020/isco-8k_20180531.htm,0.9
6/5/2018,8-K,sec_disclosure,regulatory,"On June 4, 2018, the Company filed a Current Report on Form 8-K, including Exhibit 10.1, to disclose the entry into the material definitive agreement represented by the May 31, 2018 promissory note.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018015020/isco-8k_20180531.htm,0.9
5/16/2018,8-K,sec_disclosure,corporate,"On May 14, 2018, the Company entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note for $800,000 to Dr. Andrey Semechkin, its Co-Chairman and CEO, bearing 4% annual interest and due November 1, 2018, with optional prepayment.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018013780/isco-8k_20180514.htm,0.9
4/9/2018,10-K,sec_disclosure,ip,"ISCO scientists created the first parthenogenetic, homozygous human pluripotent stem cell line that can serve as a source of immune-matched therapeutic cells for hundreds of millions of individuals.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018007802/isco-10k_20171231.htm,0.9
4/9/2018,10-K,sec_disclosure,clinical,The Company completed IND-enabling preclinical studies for its neural stem cell product candidate (ISC-hpNSC) aimed at treating Parkinson’s disease.,https://www.sec.gov/Archives/edgar/data/1355790/000156459018007802/isco-10k_20171231.htm,0.9
4/9/2018,10-K,sec_disclosure,regulatory,ISCO filed a regulatory submission (IND) with the Australian Therapeutics Goods Administration (TGA) for its ISC-hpNSC therapeutic program.,https://www.sec.gov/Archives/edgar/data/1355790/000156459018007802/isco-10k_20171231.htm,0.9
4/9/2018,10-K,sec_disclosure,clinical,The Company initiated a Phase I clinical trial in Australia to evaluate the safety and feasibility of its ISC-hpNSC therapy in Parkinson’s disease patients.,https://www.sec.gov/Archives/edgar/data/1355790/000156459018007802/isco-10k_20171231.htm,0.9
4/9/2018,10-K,sec_disclosure,clinical,"As of March 2018, ISCO successfully transplanted ISC-hpNSC cells into eight Parkinson’s disease patients as part of its ongoing Phase I study.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018007802/isco-10k_20171231.htm,0.9
3/8/2018,8-K,sec_disclosure,corporate,"On March 6, 2018, International Stem Cell Corporation entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note to its Co-Chairman and CEO, Dr. Andrey Semechkin, for up to $500,000 (with $350,000 initially funded) to finance working capital, bearing interest at 4% per annum and due November 1, 2018.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018004977/isco-8k_20180308.htm,0.9
2/21/2018,8-K,sec_disclosure,corporate,"On February 13, 2018, Jennifer Stephens, the Acting Chief Financial Officer of International Stem Cell Corporation, submitted her resignation effective March 14, 2018, and the company is evaluating alternatives to fill the principal financial officer role.",https://www.sec.gov/Archives/edgar/data/1355790/000156459018002639/isco-8k_20180213.htm,0.9
12/13/2017,8-K,sec_disclosure,corporate,"On December 7, 2017, the Company entered into a Note Conversion and Stock Purchase Agreement with its Co-Chairman and CEO, Dr. Andrey Semechkin, under which the Company agreed to issue 1,860,810 shares of common stock at $1.75 per share in exchange for cancellation of a $2.7 million note plus accrued interest and an additional $500,000 payment.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017024864/isco-8k_20171206.htm,0.9
12/13/2017,8-K,sec_disclosure,regulatory,"The 1,860,810 shares issued to Dr. Semechkin pursuant to the Agreement were sold in an unregistered transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017024864/isco-8k_20171206.htm,0.9
12/13/2017,8-K,sec_disclosure,regulatory,"Since November 13, 2017, the Company issued 20,000 shares of common stock upon conversion of a portion of its Series I-1 Convertible Preferred Stock, in reliance on the Section 3(a)(9) registration exemption.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017024864/isco-8k_20171206.htm,0.9
12/13/2017,8-K,sec_disclosure,corporate,"As a result of the Note Conversion Agreement and the preferred-stock conversions, the Company’s total common shares outstanding increased to 6,031,957 as of December 13, 2017.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017024864/isco-8k_20171206.htm,0.9
9/6/2017,8-K,sec_disclosure,corporate,"On September 1, 2017, International Stem Cell Corporation entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note for $2.7 million to Dr. Andrey Semechkin to refinance a prior $2.0 million note and provide additional working capital, bearing interest at 3.5% per annum and due December 15, 2017.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017018343/isco-8k_20170901.htm,0.9
8/25/2017,8-K,sec_disclosure,corporate,"On August 22, 2017, the Company concluded its employment relationship with Mahnaz Ebrahimi, its Chief Financial Officer, effective as of that date.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017018070/isco-8k_20170822.htm,0.9
8/25/2017,8-K,sec_disclosure,corporate,"On August 24, 2017, the Board of Directors appointed Jennifer Stephens, age 29, as acting Chief Financial Officer effective August 25, 2017.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017018070/isco-8k_20170822.htm,0.9
8/25/2017,8-K,sec_disclosure,corporate,"Jennifer Stephens was granted a stock option to purchase 80,000 shares of the Company’s common stock as part of her compensatory arrangement.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017018070/isco-8k_20170822.htm,0.9
6/8/2017,8-K,sec_disclosure,corporate,"On June 2, 2017, International Stem Cell Corporation issued an unsecured, non-convertible promissory note for $2,000,000 to its Co-Chairman and CEO, Dr. Andrey Semechkin, in exchange for surrendering a prior $1,300,000 note and providing an additional $700,000, bearing 3.5% interest per annum and due September 1, 2017.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017012287/isco-8k_20170602.htm,0.9
6/6/2017,8-K,sec_disclosure,corporate,"The Company held its Annual Meeting of Stockholders on May 31, 2017.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017012165/isco-8k_20170531.htm,0.9
6/6/2017,8-K,sec_disclosure,corporate,Stockholders elected five directors to hold office until the 2018 Annual Meeting.,https://www.sec.gov/Archives/edgar/data/1355790/000156459017012165/isco-8k_20170531.htm,0.9
6/6/2017,8-K,sec_disclosure,corporate,"Stockholders ratified the selection of Mayer Hoffman McCann, P.C. as the Company’s independent public accountants for the fiscal year ending December 31, 2017.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017012165/isco-8k_20170531.htm,0.9
6/6/2017,8-K,sec_disclosure,corporate,Stockholders provided advisory approval of the compensation of the Company’s named executive officers.,https://www.sec.gov/Archives/edgar/data/1355790/000156459017012165/isco-8k_20170531.htm,0.9
3/31/2017,10-K,sec_disclosure,regulatory,"ISCO completed IND-enabling preclinical studies on its neural stem cell program for Parkinson’s disease, paving the way for clinical development.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017005854/isco-10k_20161231.htm,0.9
3/31/2017,10-K,sec_disclosure,regulatory,The company filed a regulatory submission with the Australian Therapeutics Goods Administration (TGA) to support its neural stem cell therapy for Parkinson’s disease.,https://www.sec.gov/Archives/edgar/data/1355790/000156459017005854/isco-10k_20161231.htm,0.9
3/31/2017,10-K,sec_disclosure,clinical,ISCO initiated a Phase I clinical trial in Australia to evaluate the safety of its ISC-hpNSC neural stem cell therapy in Parkinson’s disease patients.,https://www.sec.gov/Archives/edgar/data/1355790/000156459017005854/isco-10k_20161231.htm,0.9
3/31/2017,10-K,sec_disclosure,clinical,The company successfully transplanted ISC-hpNSC cells into Parkinson’s disease patients and completed the first cohort in its ongoing clinical trial.,https://www.sec.gov/Archives/edgar/data/1355790/000156459017005854/isco-10k_20161231.htm,0.9
3/31/2017,10-K,sec_disclosure,ip,"ISCO scientists created the first parthenogenetic, homozygous human stem cell line capable of providing immune-matched cells for therapy.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017005854/isco-10k_20161231.htm,0.9
3/31/2017,10-K,sec_disclosure,regulatory,The company established facilities and manufacturing processes that comply with current Good Manufacturing Practice (GMP) standards as defined by FDA regulations.,https://www.sec.gov/Archives/edgar/data/1355790/000156459017005854/isco-10k_20161231.htm,0.9
3/31/2017,10-K,sec_disclosure,corporate,ISCO’s two commercial businesses in cosmetics and research products generated revenues of $7.2 million in 2016 and $7.6 million in 2015.,https://www.sec.gov/Archives/edgar/data/1355790/000156459017005854/isco-10k_20161231.htm,0.9
3/22/2017,8-K,sec_disclosure,corporate,"On March 20, 2017, International Stem Cell Corporation entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note for $1,300,000 to Dr. Andrey Semechkin, its Co-Chairman and CEO, to refinance existing indebtedness and provide additional working capital.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017005041/isco-8k_20170320.htm,0.9
2/28/2017,8-K,sec_disclosure,corporate,"International Stem Cell Corporation entered into an amendment to its existing facilities lease with S Real Estate Holding LLC, extending the lease term by three years until February 29, 2020, with base rent increasing by 3% each year from March 1, 2017 through February 29, 2020.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017002784/isco-8k_20170222.htm,0.9
1/18/2017,8-K,sec_disclosure,corporate,"On January 12, 2017, International Stem Cell Corporation entered into a material definitive agreement by issuing an unsecured, non-convertible $600,000 promissory note to Dr. Andrey Semechkin, its Co-Chairman and CEO, to fund working capital; the note bears interest at 3.50% per annum, is due September 1, 2017, and may be prepaid at any time without penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000156459017000382/isco-8k_20170112.htm,0.9
12/13/2016,8-K,sec_disclosure,regulatory,"On November 14, 2016, the Company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2016, reporting 3,642,696 shares of common stock outstanding as of November 12, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016030162/isco-8k_20161208.htm,0.9
12/13/2016,8-K,sec_disclosure,corporate,"On December 8, 2016, the Company issued 285,714 unregistered shares of common stock to Dr. Andrey Semechkin upon exercise of Series C warrants, raising approximately $500,000 in a private transaction under Section 4(a)(2) of the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016030162/isco-8k_20161208.htm,0.9
9/19/2016,8-K,sec_disclosure,regulatory,"On September 14, 2016, the Company filed a Current Report on Form 8-K under Item 3.02 to disclose unregistered sales of its common stock.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016025299/isco-8k_20160914.htm,0.9
9/19/2016,8-K,sec_disclosure,corporate,"Between August 23 and September 14, 2016, the Company issued 200,000 shares of common stock to its Co-Chairman and CEO, Dr. Andrey Semechkin, upon cash exercise of Series B warrants, receiving $350,000 in private‐transaction consideration.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016025299/isco-8k_20160914.htm,0.9
8/24/2016,8-K,sec_disclosure,corporate,"On August 15, 2016, the Company filed its Quarterly Report on Form 10-Q for the period ended June 30, 2016, reporting 3,231,236 shares of common stock outstanding as of August 12, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016024649/isco-8k_20160822.htm,0.9
8/24/2016,8-K,sec_disclosure,corporate,"Between August 13 and August 22, 2016, the Company issued 20,000 shares of common stock upon conversion of Series I-1 Convertible Preferred Stock in reliance on the exemption provided by Section 3(a)(9) of the Securities Act of 1933.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016024649/isco-8k_20160822.htm,0.9
8/24/2016,8-K,sec_disclosure,corporate,"On August 22, 2016, the Company issued 154,285 shares of common stock to Co-Chairman and CEO Dr. Andrey Semechkin upon his cash exercise of Series B Warrants (yielding approximately $270,000), relying on the Section 4(a)(2) exemption of the Securities Act of 1933.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016024649/isco-8k_20160822.htm,0.9
8/24/2016,8-K,sec_disclosure,corporate,"As a result of these unregistered issuances, the total shares of common stock outstanding increased by more than 5% over the amount reported in the August Quarterly Report, reaching 3,396,521 shares as of August 22, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016024649/isco-8k_20160822.htm,0.9
5/19/2016,8-K,sec_disclosure,corporate,"The Company held its 2016 Annual Meeting of Stockholders on May 13, 2016, at which several governance and corporate matters were presented for vote.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516594721/d69037d8k.htm,0.9
5/19/2016,8-K,sec_disclosure,corporate,Shareholders elected five directors—two by Series D Preferred Stock holders and three by all stockholders—to serve until the 2017 Annual Meeting.,https://www.sec.gov/Archives/edgar/data/1355790/000119312516594721/d69037d8k.htm,0.9
5/19/2016,8-K,sec_disclosure,corporate,"Shareholders ratified the selection of Mayer Hoffman McCann, P.C. as the Company’s independent public accountants for the fiscal year ending December 31, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516594721/d69037d8k.htm,0.9
5/19/2016,8-K,sec_disclosure,corporate,"On an advisory basis, shareholders approved the compensation of the Company’s named executive officers as disclosed in the proxy statement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516594721/d69037d8k.htm,0.9
5/19/2016,8-K,sec_disclosure,corporate,"Shareholders approved an amendment to the Company’s Certificate of Incorporation to decrease the number of authorized shares of Common Stock to 120,000,000.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516594721/d69037d8k.htm,0.9
5/19/2016,8-K,sec_disclosure,corporate,Shareholders approved amendments to the Company’s 2010 Equity Participation Plan to adjust its terms and share reserve.,https://www.sec.gov/Archives/edgar/data/1355790/000119312516594721/d69037d8k.htm,0.9
5/19/2016,8-K,sec_disclosure,corporate,"On May 13, 2016, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Delaware Secretary of State, reducing the authorized common stock to 120,000,000 shares.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516594721/d69037d8k.htm,0.9
5/16/2016,10-Q,sec_disclosure,corporate,The company effected a reverse stock split as described in Note 1 to the financial statements to consolidate its outstanding shares.,https://www.sec.gov/Archives/edgar/data/1355790/000156459016019502/isco-10q_20160331.htm,0.9
5/16/2016,10-Q,sec_disclosure,corporate,"During the quarter, the company issued common stock in exchange for services rendered to the company.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016019502/isco-10q_20160331.htm,0.9
5/16/2016,10-Q,sec_disclosure,corporate,"The company obtained a $700,000 bridge loan from a related party during the three months ended March 31, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016019502/isco-10q_20160331.htm,0.9
5/16/2016,10-Q,sec_disclosure,corporate,The company raised $2.5 million through the issuance of Series I-1 and I-2 convertible preferred stock in Q1 2016.,https://www.sec.gov/Archives/edgar/data/1355790/000156459016019502/isco-10q_20160331.htm,0.9
5/16/2016,10-Q,sec_disclosure,corporate,The $3.81 million bridge loan from a related party was converted into equity during the quarter.,https://www.sec.gov/Archives/edgar/data/1355790/000156459016019502/isco-10q_20160331.htm,0.9
5/16/2016,10-Q,sec_disclosure,ip,"The company paid approximately $160,000 for patent licenses and trademarks in the three months ended March 31, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016019502/isco-10q_20160331.htm,0.9
3/30/2016,10-K,sec_disclosure,clinical,Completed IND-enabling preclinical studies on its neural stem cell program for the treatment of Parkinson’s disease.,https://www.sec.gov/Archives/edgar/data/1355790/000156459016015688/isco-10k_20151231.htm,0.9
3/30/2016,10-K,sec_disclosure,regulatory,Filed a regulatory submission with the Australian Therapeutics Goods Administration (TGA) to initiate a Phase 1/2a clinical trial in Australia for its neural stem cell therapy.,https://www.sec.gov/Archives/edgar/data/1355790/000156459016015688/isco-10k_20151231.htm,0.9
3/30/2016,10-K,sec_disclosure,corporate,Incorporated information from its definitive Proxy Statement for the 2016 Annual Meeting of Stockholders by reference into Part III of this Form 10-K.,https://www.sec.gov/Archives/edgar/data/1355790/000156459016015688/isco-10k_20151231.htm,0.9
3/30/2016,10-K,sec_disclosure,corporate,"Named to Deloitte’s 2014 Technology Fast 500™ list on December 16, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000156459016015688/isco-10k_20151231.htm,0.9
3/10/2016,8-K,sec_disclosure,corporate,"On March 9, 2016, the Company entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note for $3,810,000 to its Co-Chairman and CEO, Dr. Andrey Semechkin, to refinance indebtedness incurred on January 8, 2016. The note bears interest at 0.50% per annum, is due April 10, 2016, and may be prepaid without penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516499904/d303172d8k.htm,0.9
3/3/2016,8-K,sec_disclosure,corporate,"On March 3, 2016, International Stem Cell Corporation amended its existing facilities lease with S Real Estate Holding LLC, extending the lease term by one year to February 28, 2017 and increasing monthly rent by 3%.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516491780/d155198d8k.htm,0.9
1/12/2016,8-K,sec_disclosure,corporate,"On January 8, 2016, the Company issued an unsecured, non-convertible promissory note in the principal amount of $3,810,000 to Dr. Andrey Semechkin to refinance existing indebtedness and provide additional working capital.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516428063/d100601d8k.htm,0.9
1/12/2016,8-K,sec_disclosure,corporate,"On January 8, 2016, the Company entered into a Note Conversion Agreement with Dr. Semechkin, providing for the conversion of the January 8, 2016 promissory note (principal and accrued interest) into common stock and Series A and B warrants on terms equivalent to those in the proposed S-1 offering.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516428063/d100601d8k.htm,0.9
1/12/2016,8-K,sec_disclosure,regulatory,"On January 8, 2016, the Company entered into a Registration Rights Agreement with Dr. Semechkin, granting him the right to demand registration of the common stock and warrants issuable to him (and certain related securities) on a Form S-3 or similar continuous registration statement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312516428063/d100601d8k.htm,0.9
12/15/2015,8-K,sec_disclosure,corporate,"On December 10, 2015, International Stem Cell Corporation issued an unsecured, non-convertible promissory note for $3,110,000 to its Co-Chairman and CEO, Dr. Andrey Semechkin, bearing interest at 0.50% per annum and due January 10, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515402789/d104429d8k.htm,0.9
12/15/2015,8-K,sec_disclosure,corporate,"Concurrently, Dr. Semechkin surrendered the Company’s November 3, 2015 promissory note in the principal amount of $2,862,000 as part of the refinancing transaction.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515402789/d104429d8k.htm,0.9
12/15/2015,8-K,sec_disclosure,corporate,"As part of the same refinancing, Dr. Semechkin provided an additional $248,000 of working capital to International Stem Cell Corporation.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515402789/d104429d8k.htm,0.9
12/15/2015,8-K,sec_disclosure,regulatory,"Pursuant to Item 2.03 of Form 8-K, the Company recognized the issuance of the new promissory note as the creation of a direct financial obligation.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515402789/d104429d8k.htm,0.9
12/14/2015,8-K,sec_disclosure,regulatory,The Therapeutic Goods Administration of Australia cleared the Company’s regulatory submission to initiate a Phase I/IIa dose-escalation trial of human parthenogenetic stem cell-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson’s disease.,https://www.sec.gov/Archives/edgar/data/1355790/000119312515401779/d85000d8k.htm,0.9
12/14/2015,8-K,sec_disclosure,clinical,The Company will initiate a Phase I/IIa clinical trial to evaluate ISC-hpNSC in patients with moderate to severe Parkinson’s disease under a dose-escalation design.,https://www.sec.gov/Archives/edgar/data/1355790/000119312515401779/d85000d8k.htm,0.9
12/4/2015,8-K,sec_disclosure,corporate,"Between November 2014 and November 2015, holders of all Series H-1 and Series H-2 Preferred Stock converted their shares into common stock, resulting in no outstanding shares of these preferred series.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515395566/d43307d8k.htm,0.9
12/4/2015,8-K,sec_disclosure,corporate,"On December 3, 2015, the company filed a Certificate of Elimination for its Series H-1 Preferred Stock, amending its Certificate of Incorporation to eliminate the powers, designations, preferences, privileges, and other rights of that series.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515395566/d43307d8k.htm,0.9
12/4/2015,8-K,sec_disclosure,corporate,"On December 3, 2015, the company filed a Certificate of Elimination for its Series H-2 Preferred Stock, amending its Certificate of Incorporation to eliminate the powers, designations, preferences, privileges, and other rights of that series.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515395566/d43307d8k.htm,0.9
11/30/2015,8-K,sec_disclosure,regulatory,"On November 12, 2015, the Company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2015 with the SEC.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515390593/d220193d8k.htm,0.9
11/30/2015,8-K,sec_disclosure,corporate,"From November 10 through November 23, 2015, the Company issued an additional 278,816 shares of common stock in unregistered transactions, resulting in an increase of over 5% in shares outstanding compared to its last reported amount.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515390593/d220193d8k.htm,0.9
11/30/2015,8-K,sec_disclosure,corporate,"The Company issued 278,816 shares of common stock to Dr. Andrey Semechkin and Dr. Russell Kern upon conversion of their Series H-1 Convertible Preferred Stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515390593/d220193d8k.htm,0.9
11/30/2015,8-K,sec_disclosure,regulatory,The shares issued upon conversion of Series H-1 Convertible Preferred Stock were issued in reliance on the exemption from registration under Section 3(a)(9) of the Securities Act of 1933.,https://www.sec.gov/Archives/edgar/data/1355790/000119312515390593/d220193d8k.htm,0.9
11/4/2015,8-K,sec_disclosure,corporate,"On November 3, 2015, International Stem Cell Corporation issued an unsecured, non-convertible promissory note in the principal amount of $2,862,000 to Co-Chairman and CEO Dr. Andrey Semechkin, refinancing the note originally issued on October 9, 2015, at an interest rate of 0.5% per annum and maturing January 10, 2016.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515366222/d72055d8k.htm,0.9
11/4/2015,8-K,sec_disclosure,regulatory,The issuance of the promissory note under Item 2.03 created a direct financial obligation for the Company by establishing the refinanced indebtedness as an on-balance sheet liability.,https://www.sec.gov/Archives/edgar/data/1355790/000119312515366222/d72055d8k.htm,0.9
11/4/2015,8-K,sec_disclosure,regulatory,"The Company filed the form of the November 3, 2015 promissory note as Exhibit 10.1 to this Current Report on Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515366222/d72055d8k.htm,0.9
10/13/2015,8-K,sec_disclosure,corporate,"On October 14, 2014, the Company issued Series C Warrants in connection with a financing transaction, representing the right to acquire approximately 73,000 shares.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515341968/d36861d8k.htm,0.9
10/13/2015,8-K,sec_disclosure,corporate,"On October 10, 2015, the Company and holders of the outstanding Series C Warrants amended those warrants to extend the termination date to November 14, 2015.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515341968/d36861d8k.htm,0.9
9/14/2015,8-K,sec_disclosure,corporate,"On September 11, 2015, the Board of Directors of International Stem Cell Corporation appointed Mahnaz Ebrahimi as the Company’s new Chief Financial Officer, effective September 14, 2015.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515319273/d78872d8k.htm,0.9
9/14/2015,8-K,sec_disclosure,corporate,"Ms. Ebrahimi will transition from her consulting role to an employment relationship beginning September 14, 2015, working part-time (four days per week) for her first 90 days to complete other consulting commitments.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515319273/d78872d8k.htm,0.9
9/14/2015,8-K,sec_disclosure,corporate,"For the initial 90-day period, Ms. Ebrahimi’s annualized compensation is set at $187,500, subject to review and adjustment after those 90 days, and she will receive the Company’s standard medical and dental benefits package.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515319273/d78872d8k.htm,0.9
9/14/2015,8-K,sec_disclosure,corporate,"Ms. Ebrahimi will be granted a stock option to purchase 65,000 shares of International Stem Cell Corporation’s common stock as part of her compensatory arrangement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515319273/d78872d8k.htm,0.9
9/9/2015,8-K,sec_disclosure,corporate,"On September 9, 2015, International Stem Cell Corporation issued an unsecured, non-convertible promissory note in the principal amount of $2,862,000 to its Co-Chairman and CEO, Dr. Andrey Semechkin, to refinance a prior $2,562,000 note and obtain an additional $300,000 of working capital funding.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515315997/d85240d8k.htm,0.9
8/13/2015,8-K,sec_disclosure,corporate,"On August 10, 2015, the Company issued an unsecured, non-convertible promissory note in the principal amount of $2,562,000 to Dr. Andrey Semechkin to refinance existing indebtedness and provide additional working capital.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515290191/d59203d8k.htm,0.9
8/13/2015,8-K,sec_disclosure,corporate,The promissory note described under Item 1.01 constitutes a new direct financial obligation of the Company as set forth under Item 2.03 of the Form 8-K.,https://www.sec.gov/Archives/edgar/data/1355790/000119312515290191/d59203d8k.htm,0.9
8/13/2015,8-K,sec_disclosure,regulatory,"The Company filed the form of the promissory note as Exhibit 10.1 to this Current Report on Form 8-K, satisfying its SEC exhibit filing requirement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515290191/d59203d8k.htm,0.9
8/13/2015,10-Q,sec_disclosure,corporate,"The company implemented a reverse stock split, as referenced in Note 1 of the financial statements, consolidating outstanding shares at a specified ratio to reduce the number of shares outstanding.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/13/2015,10-Q,sec_disclosure,corporate,"International Stem Cell Corporation issued common stock during the period through cash subscriptions, services, warrant exercises, and other share issuances, resulting in increases to paid-in capital.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/13/2015,10-Q,sec_disclosure,corporate,"Series H-1 Convertible Preferred Stock was converted into common shares during the period, reducing preferred shares outstanding and increasing common stock and additional paid-in capital.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/13/2015,10-Q,sec_disclosure,corporate,"The redemption feature of the Series G Convertible Preferred Stock was formally waived, altering the terms of the preferred stock without new share issuances.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/13/2015,10-Q,sec_disclosure,corporate,"The company recognized changes in the fair value of its warrant liability, recorded a warrant exchange inducement expense, and incurred a warrant modification expense related to outstanding warrants.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/13/2015,10-Q,sec_disclosure,corporate,"A bridge loan of $2,262,000 was obtained from a related party, providing additional liquidity during the period.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/13/2015,10-Q,sec_disclosure,ip,"Payments totaling $336,000 were made for patent licenses and trademarks, representing ongoing investments in the company’s intellectual property portfolio.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/13/2015,10-Q,sec_disclosure,regulatory,"The company filed its Quarterly Report on Form 10-Q for the period ended June 30, 2015, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015007278/isco-10q_20150630.htm,0.9
8/11/2015,8-K,sec_disclosure,corporate,"On May 11, 2015, the Company filed its Quarterly Report on Form 10-Q for the period ended March 31, 2015, reporting 1,804,833 shares outstanding as of May 5, 2015.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515286271/d66017d8k.htm,0.9
8/11/2015,8-K,sec_disclosure,corporate,"Between May 6, 2015 and August 5, 2015, the Company issued an additional 96,341 shares of common stock in transactions not registered under the Securities Act of 1933.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515286271/d66017d8k.htm,0.9
8/11/2015,8-K,sec_disclosure,regulatory,"On August 5, 2015, the share issuances caused the number of shares outstanding to increase by more than 5% compared to the count reported in the May Quarterly Report, triggering Form 8-K disclosure under Item 3.02.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515286271/d66017d8k.htm,0.9
8/11/2015,8-K,sec_disclosure,corporate,"The Company issued a total of 92,706 shares of common stock upon conversion of a portion of its Series H-1 Convertible Preferred Stock, relying on the Section 3(a)(9) exemption from registration.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515286271/d66017d8k.htm,0.9
8/11/2015,8-K,sec_disclosure,corporate,"On June 30, 2015, the Company granted Restricted Stock Awards totaling 3,635 shares of common stock to non-employee consultants in exchange for their services.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515286271/d66017d8k.htm,0.9
8/11/2015,8-K,sec_disclosure,corporate,"On July 29, 2015, the Company effected a 150-for-1 reverse stock split, and all share numbers reported have been adjusted accordingly.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515286271/d66017d8k.htm,0.9
7/28/2015,8-K,sec_disclosure,corporate,"At a special meeting on December 4, 2014, the Company’s stockholders authorized the Board to amend the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-50 and 1-for-150 shares, with the final ratio to be determined by the Board.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515265782/d19067d8k.htm,0.9
7/28/2015,8-K,sec_disclosure,corporate,"On July 21, 2015, the Board of Directors set the specific reverse stock split ratio at one-for-one-hundred-fifty (1:150) and approved the final form of the Certificate of Amendment to effectuate the reverse split.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515265782/d19067d8k.htm,0.9
7/28/2015,8-K,sec_disclosure,corporate,"The Certificate of Amendment to the Company’s Certificate of Incorporation was filed with the Secretary of State of Delaware on July 22, 2015 to implement the approved one-for-150 reverse stock split.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515265782/d19067d8k.htm,0.9
7/28/2015,8-K,sec_disclosure,corporate,"The reverse stock split became effective at 12:01 a.m. Eastern Daylight Time on July 29, 2015, automatically combining every 150 shares of common stock into one share and rounding up fractional shares to whole shares.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515265782/d19067d8k.htm,0.9
7/28/2015,8-K,sec_disclosure,corporate,"Beginning with the market open on July 29, 2015, the Company’s common stock began trading on the OTC QB on a reverse-split-adjusted basis under a new CUSIP number (460378201).",https://www.sec.gov/Archives/edgar/data/1355790/000119312515265782/d19067d8k.htm,0.9
7/28/2015,8-K,sec_disclosure,corporate,"As a result of the reverse stock split, the per-share exercise price and number of shares issuable upon exercise of outstanding options and warrants, upon conversion of preferred stock, and under the Company’s equity participation plans were proportionately adjusted.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515265782/d19067d8k.htm,0.9
6/5/2015,8-K,sec_disclosure,corporate,"On June 3, 2015, International Stem Cell Corporation and Dr. John Simon Craw agreed that his employment as Executive Vice President of Business Development would conclude on June 5, 2015.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515215102/d938490d8k.htm,0.9
6/5/2015,8-K,sec_disclosure,corporate,"Dr. Craw will receive a severance payment of $55,000 in connection with the conclusion of his employment.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515215102/d938490d8k.htm,0.9
6/5/2015,8-K,sec_disclosure,corporate,"Following the end of his employment, Dr. Craw will continue to assist the Company in a consulting capacity.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515215102/d938490d8k.htm,0.9
5/14/2015,8-K,sec_disclosure,corporate,"On May 12, 2015, the Company entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note for $2,262,000 to Dr. Andrey Semechkin, its Co-Chairman and CEO, in exchange for surrendering his prior note and providing $2 million of additional funds.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515188021/d926884d8k.htm,0.9
5/14/2015,8-K,sec_disclosure,corporate,"In connection with the Note, the Company created a direct financial obligation payable on August 10, 2015, accruing interest at 0.50% per annum and prepayable by the Company without penalty.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515188021/d926884d8k.htm,0.9
5/14/2015,8-K,sec_disclosure,regulatory,"The form of the Note issued on May 12, 2015 was filed as Exhibit 10.1 to this Current Report on Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515188021/d926884d8k.htm,0.9
5/11/2015,8-K,sec_disclosure,corporate,"The Company held its Annual Meeting of Stockholders on May 7, 2015, during which stockholders considered four proposals.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515180149/d923724d8k.htm,0.9
5/11/2015,8-K,sec_disclosure,corporate,"Stockholders elected five directors to hold office until the 2016 Annual Meeting, electing Andrey Semechkin, Ruslan Semechkin, Donald A. Wright, Paul V. Maier, and Charles J. Casamento.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515180149/d923724d8k.htm,0.9
5/11/2015,8-K,sec_disclosure,corporate,"Stockholders ratified the selection of Mayer Hoffman McCann, P.C. as the Company’s independent public accountants for the fiscal year ending December 31, 2015.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515180149/d923724d8k.htm,0.9
5/11/2015,8-K,sec_disclosure,corporate,"On an advisory basis, stockholders approved the compensation of the Company’s named executive officers as disclosed in the proxy statement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515180149/d923724d8k.htm,0.9
5/11/2015,8-K,sec_disclosure,corporate,Stockholders approved amendments to the Company’s 2010 Equity Participation Plan.,https://www.sec.gov/Archives/edgar/data/1355790/000119312515180149/d923724d8k.htm,0.9
5/8/2015,8-K,sec_disclosure,corporate,"On May 6, 2015, the Company entered into a material definitive agreement by issuing an unsecured, non-convertible promissory note in the principal amount of $262,000 to its Co-Chairman and CEO, Dr. Andrey Semechkin, accruing interest at 0.45% per annum and due May 15, 2015.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515177711/d924781d8k.htm,0.9
5/8/2015,8-K,sec_disclosure,regulatory,"The Company filed the form of the promissory note as Exhibit 10.1 to its Current Report on Form 8-K dated May 6, 2015.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515177711/d924781d8k.htm,0.9
4/30/2015,8-K,sec_disclosure,corporate,"Jay Novak, the Chief Financial Officer of International Stem Cell Corporation, submitted his resignation on April 27, 2015, effective May 8, 2015, to pursue a new career opportunity.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515162128/d919252d8k.htm,0.9
4/23/2015,8-K,sec_disclosure,corporate,"Between March 26 and April 22, 2015, the Company issued an additional 13,722,045 shares of common stock in unregistered transactions, resulting in a more than 5% increase in shares outstanding compared to the March 2015 Annual Report.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515142381/d906788d8k.htm,0.9
4/23/2015,8-K,sec_disclosure,corporate,"The Company issued 5,966,500 shares of common stock to holders of its Series H-1 Convertible Preferred Stock upon conversion of a portion of those preferred shares, in reliance on the Section 3(a)(9) exemption from registration.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515142381/d906788d8k.htm,0.9
4/23/2015,8-K,sec_disclosure,corporate,"Dr. Ruslan Semechkin and Dr. Andrey Semechkin exercised Series C warrants for cash, resulting in the issuance of 1,861,331 and 5,894,214 shares of common stock, respectively, and the Company received $347,000 in aggregate consideration under the Section 4(a)(2) private placement exemption.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515142381/d906788d8k.htm,0.9
4/15/2015,8-K,sec_disclosure,corporate,"On October 14, 2014, the Company issued Series B warrants (among other securities) in connection with a financing transaction, as previously reported on Form 8-K filed October 8, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515129822/d909092d8k.htm,0.9
4/15/2015,8-K,sec_disclosure,corporate,"On April 14, 2015, the Company and holders of the outstanding Series B warrants amended those warrants to extend the termination date to June 20, 2015; set the exercise price at $0.075 per share; and remove certain price reset, cashless exercise, participation rights, and anti-dilution provisions.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515129822/d909092d8k.htm,0.9
4/1/2015,8-K,sec_disclosure,corporate,"On March 31, 2015, International Stem Cell Corporation issued a press release reporting its financial results for the year ended December 31, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515116351/d902056d8k.htm,0.9
4/1/2015,8-K,sec_disclosure,regulatory,"On April 1, 2015, the company filed a Form 8-K with the SEC and furnished Exhibit 99.1 (the March 31, 2015 press release) under Item 2.02 and Item 9.01 of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515116351/d902056d8k.htm,0.9
3/30/2015,10-K,sec_disclosure,ip,"In 2013, the company published a paper in Nature Scientific Reports describing a new method for manufacturing neural stem cells, which forms the basis for its related patent applications on neural stem cell production.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015002078/isco-10k_20141231.htm,0.9
3/30/2015,10-K,sec_disclosure,clinical,"In 2014, ISCO completed the majority of its preclinical safety research on neural stem cells across multiple animal species, including non-human primates, to establish a safety profile ahead of human trials.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015002078/isco-10k_20141231.htm,0.9
3/30/2015,10-K,sec_disclosure,clinical,"The company anticipates commencing a Phase I clinical trial of its neural stem cell therapy for Parkinson’s disease in Australia in 2015, marking the start of its first-in-human studies.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015002078/isco-10k_20141231.htm,0.9
3/30/2015,10-K,sec_disclosure,clinical,"In August 2014, ISCO initiated evaluation of neural stem cell transplantation for the treatment of ischemic stroke using a rodent disease model, leveraging existing safety data from its Parkinson’s program.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015002078/isco-10k_20141231.htm,0.9
3/30/2015,10-K,sec_disclosure,corporate,"For the years ended December 31, 2014 and 2013, ISCO generated $7.0 million and $6.1 million, respectively, in revenue from its cosmeceutical and biomedical research product businesses.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015002078/isco-10k_20141231.htm,0.9
3/30/2015,10-K,sec_disclosure,regulatory,ISCO established facilities and manufacturing protocols that comply with Good Manufacturing Practice (GMP) standards as enforced by the U.S. Food and Drug Administration to support future clinical-grade product production.,https://www.sec.gov/Archives/edgar/data/1355790/000156459015002078/isco-10k_20141231.htm,0.9
3/30/2015,10-K,sec_disclosure,ip,"The company developed its proprietary UniStemCell collection by creating the first parthenogenetic, homozygous human stem cell line and expanding to a total of fifteen hpSC lines for broad therapeutic use.",https://www.sec.gov/Archives/edgar/data/1355790/000156459015002078/isco-10k_20141231.htm,0.9
1/7/2015,8-K,sec_disclosure,corporate,"On December 31, 2014, the Company entered into a Waiver Agreement with all holders of its Series G Preferred Stock, irrevocably waiving their rights to require redemption of their shares and related payments under the Series G Certificate of Designation, which enables the reclassification of the Series G Preferred Stock from mezzanine equity to permanent equity.",https://www.sec.gov/Archives/edgar/data/1355790/000119312515003853/d846584d8k.htm,0.9
12/29/2014,8-K,sec_disclosure,corporate,"From November 13 to December 22, 2014, the Company issued 14,894,214 shares of common stock in unregistered transactions, resulting in an increase of more than 5% in outstanding shares compared to the last quarterly report.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514454209/d842829d8k.htm,0.9
12/29/2014,8-K,sec_disclosure,corporate,"The Company issued 9,000,000 shares of common stock to holders of Series H-1 Convertible Preferred Stock upon conversion of a portion of those preferred shares in reliance on the exemption under Section 3(a)(9) of the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514454209/d842829d8k.htm,0.9
12/29/2014,8-K,sec_disclosure,corporate,"The Company issued 5,894,214 shares of common stock to Dr. Andrey Semechkin upon his cash exercise of Series B warrants, receiving $340,000 in a private placement transaction under Section 4(a)(2) of the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514454209/d842829d8k.htm,0.9
12/29/2014,8-K,sec_disclosure,regulatory,"The Company filed a Current Report on Form 8-K with the SEC on December 26, 2014, reporting the unregistered sales of equity securities.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514454209/d842829d8k.htm,0.9
12/5/2014,8-K,sec_disclosure,corporate,"International Stem Cell Corporation held a Special Meeting of Stockholders on December 4, 2014 to vote on proposed amendments to its Certificate of Incorporation.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514434862/d836202d8k.htm,0.9
12/5/2014,8-K,sec_disclosure,corporate,"Following stockholder approval, the Company filed a Certificate of Amendment on December 4, 2014 to increase its authorized common stock from 600,000,000 to 720,000,000 shares.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514434862/d836202d8k.htm,0.9
12/5/2014,8-K,sec_disclosure,corporate,"At the Special Meeting, stockholders approved an amendment to increase the number of authorized shares of common stock from 600 million to 720 million.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514434862/d836202d8k.htm,0.9
12/5/2014,8-K,sec_disclosure,corporate,"At the same meeting, stockholders approved an amendment to permit a reverse stock split of common stock at a ratio between one-for-fifty and one-for-one-hundred-fifty, at the Board’s discretion.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514434862/d836202d8k.htm,0.9
11/18/2014,8-K,sec_disclosure,corporate,"On November 13, 2014, the Company entered into an amendment to its Amended and Restated Investor Rights Agreement, modifying investor participation provisions in future financings.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514416506/d823049d8k.htm,0.9
11/18/2014,8-K,sec_disclosure,corporate,"The amendment terminates overlapping participation rights under the Investor Rights Agreement for the 18-month period following the closing of the October 7, 2014 Securities Purchase Agreement (through April 14, 2016).",https://www.sec.gov/Archives/edgar/data/1355790/000119312514416506/d823049d8k.htm,0.9
11/18/2014,8-K,sec_disclosure,corporate,"The amendment restores investor participation rights in any Subsequent Financing after April 14, 2016, allowing investors to subscribe in proportion to their ownership percentage on the same terms as the financing.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514416506/d823049d8k.htm,0.9
11/18/2014,8-K,sec_disclosure,corporate,"The previously disclosed Securities Purchase Agreement, dated October 7, 2014, granted certain investors, including two directors and affiliated entities, participation rights in subsequent financings for 18 months post-closing.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514416506/d823049d8k.htm,0.9
11/13/2014,10-Q,sec_disclosure,corporate,"On December 28, 2006, BTHC III, Inc. completed a Share Exchange to acquire all of the outstanding stock of International Stem Cell Corporation (ISC California), after which ISC California’s former shareholders owned 93.7% of the combined company.",https://www.sec.gov/Archives/edgar/data/1355790/000156459014005595/isco-10q_20140930.htm,0.9
11/13/2014,10-Q,sec_disclosure,corporate,"During 2013 and the nine months ended September 30, 2014, the company issued common stock through multiple financings, including conversion of Series C preferred shares, exercises of warrants and options, cash offerings (net of issuance costs), and equity issuances for services rendered.",https://www.sec.gov/Archives/edgar/data/1355790/000156459014005595/isco-10q_20140930.htm,0.9
11/13/2014,10-Q,sec_disclosure,corporate,"In the nine months ended September 30, 2014, the company implemented a warrant exchange program that included inducement expenses and reclassification of warrant liabilities into equity upon exchange.",https://www.sec.gov/Archives/edgar/data/1355790/000156459014005595/isco-10q_20140930.htm,0.9
11/13/2014,10-Q,sec_disclosure,ip,"The company made cash payments for patent licenses and trademarks during the nine months ended September 30, 2014 (and comparative period in 2013) to maintain and expand its intellectual property portfolio.",https://www.sec.gov/Archives/edgar/data/1355790/000156459014005595/isco-10q_20140930.htm,0.9
11/13/2014,8-K,sec_disclosure,corporate,"On November 13, 2014, the company issued a press release reporting its financial results for the third quarter ended September 30, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514410396/d823264d8k.htm,0.9
11/13/2014,8-K,sec_disclosure,regulatory,"On November 13, 2014, International Stem Cell Corporation filed a Form 8-K to furnish its press release under Item 2.02, reporting its third quarter financial results.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514410396/d823264d8k.htm,0.9
10/8/2014,8-K,sec_disclosure,corporate,"On October 7, 2014, the Company entered into a Securities Purchase Agreement with two institutional investors and its executive officers to issue Series H-1 and H-2 convertible preferred stock and Series A, B and C warrants in a private offering.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514366188/d800720d8k.htm,0.9
10/8/2014,8-K,sec_disclosure,corporate,The Securities Purchase Agreement requires the Company to hold a stockholders’ meeting within 60 days of closing to approve a reverse stock split and amend its certificate of incorporation to increase authorized common shares.,https://www.sec.gov/Archives/edgar/data/1355790/000119312514366188/d800720d8k.htm,0.9
10/8/2014,8-K,sec_disclosure,corporate,"The Company engaged H.C. Wainwright & Co. as exclusive placement agent pursuant to a September 23, 2014 engagement letter, under which the agent will receive a $200,000 fee, a warrant to purchase approximately 9.3 million shares, and expense reimbursement upon closing.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514366188/d800720d8k.htm,0.9
10/8/2014,8-K,sec_disclosure,regulatory,"The Company entered into a Registration Rights Agreement obligating it to file and obtain effectiveness of a registration statement for resale of shares issuable upon conversion of the preferred stock and exercise of the warrants within specified timeframes, with penalty provisions for delays.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514366188/d800720d8k.htm,0.9
10/8/2014,8-K,sec_disclosure,regulatory,"The issuance and sale of the preferred stock and warrants under the Purchase Agreement were conducted in an exempt transaction under Section 4(a)(2) of the Securities Act and Rule 506(b), constituting unregistered sales of equity securities.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514366188/d800720d8k.htm,0.9
10/8/2014,8-K,sec_disclosure,corporate,"Prior to closing, the Company intends to file Certificates of Designation with the Delaware Secretary of State to establish and designate the rights, preferences, privileges, and limitations of the Series H-1 and H-2 convertible preferred stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514366188/d800720d8k.htm,0.9
10/8/2014,8-K,sec_disclosure,corporate,"On October 8, 2014, the Company issued a press release announcing the private offering of preferred stock and warrants to its investors.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514366188/d800720d8k.htm,0.9
9/16/2014,8-K,sec_disclosure,corporate,"On September 10, 2014, International Stem Cell Corporation entered into a Securities Purchase Agreement with Dr. Andrey Semechkin and Dr. Ruslan Semechkin to sell 4,444,445 shares of common stock at $0.09 per share for $400,000 to fund working capital.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514343068/d790953d8k.htm,0.9
9/16/2014,8-K,sec_disclosure,regulatory,"The private placement transaction of 4,444,445 shares was completed on September 10, 2014, with the shares offered and sold in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514343068/d790953d8k.htm,0.9
9/16/2014,8-K,sec_disclosure,regulatory,"The company filed Exhibit 10.1, the Securities Purchase Agreement dated September 10, 2014, as part of its Form 8-K on September 16, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514343068/d790953d8k.htm,0.9
8/12/2014,8-K,sec_disclosure,corporate,"On August 12, 2014, the Company issued a press release reporting its financial results for the second quarter ended June 30, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514305800/d773722d8k.htm,0.9
8/12/2014,8-K,sec_disclosure,regulatory,"The Company furnished Exhibit 99.1 (the August 12, 2014 press release) under Item 2.02 of its Form 8-K current report.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514305800/d773722d8k.htm,0.9
8/11/2014,8-K,sec_disclosure,corporate,"On August 6, 2014, International Stem Cell Corporation entered into a Securities Purchase Agreement with Dr. Andrey Semechkin and Dr. Ruslan Semechkin to sell 6,000,000 shares of common stock at $0.10 per share for total proceeds of $600,000 in a private placement transaction.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514303794/d774543d8k.htm,0.9
7/1/2014,8-K,sec_disclosure,corporate,"International Stem Cell Corporation entered into a Securities Purchase Agreement on June 26, 2014 to sell 5,500,000 shares of common stock at $0.10 per share to Dr. Andrey Semechkin and Dr. Ruslan Semechkin for total proceeds of $550,000.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514256608/d752895d8k.htm,0.9
7/1/2014,8-K,sec_disclosure,corporate,"The sale of 5,500,000 shares of common stock to the purchasers was completed on June 26, 2014 in a private placement transaction.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514256608/d752895d8k.htm,0.9
7/1/2014,8-K,sec_disclosure,regulatory,"The private placement was conducted in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D, with each purchaser qualifying as an accredited investor under Rule 501.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514256608/d752895d8k.htm,0.9
6/12/2014,8-K,sec_disclosure,corporate,"On June 11, 2014, the Company entered into Warrant Exchange Agreements with holders of its Series A Warrants and Placement Agent Warrants, agreeing to issue 44,665,783 shares of common stock in exchange for cancellation of warrants to purchase 36,554,822 shares and placement agent warrants for 666,666 shares.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514234067/d743018d8k.htm,0.9
6/12/2014,8-K,sec_disclosure,corporate,"The Company expects to close the warrant exchanges on June 16, 2014, completing the issuance of 44,665,783 shares of common stock in exchange for outstanding warrants.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514234067/d743018d8k.htm,0.9
6/12/2014,8-K,sec_disclosure,regulatory,"The issuance of 44,665,783 shares in exchange for previously issued warrants is exempt from registration under Section 3(a)(9) of the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514234067/d743018d8k.htm,0.9
6/12/2014,8-K,sec_disclosure,regulatory,"Since May 2, 2014, the Company sold 3,333,333 shares of common stock to its directors and executive officers in a private placement transaction relying on the Section 4(a)(2) exemption from registration under the Securities Act of 1933.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514234067/d743018d8k.htm,0.9
5/14/2014,8-K,sec_disclosure,corporate,"On May 8, 2014, the Company filed a Certificate of Amendment to its Certificate of Incorporation to increase its authorized common stock from 300 million shares to 600 million shares.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514198873/d726732d8k.htm,0.9
5/14/2014,8-K,sec_disclosure,corporate,"The Company held its 2014 Annual Meeting of Stockholders on May 8, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514198873/d726732d8k.htm,0.9
5/14/2014,8-K,sec_disclosure,corporate,"At the 2014 Annual Meeting, stockholders elected five directors (Andrey Semechkin, Ruslan Semechkin, Donald A. Wright, Paul V. Maier and Charles J. Casamento) to serve until the 2015 Annual Meeting.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514198873/d726732d8k.htm,0.9
5/14/2014,8-K,sec_disclosure,corporate,"At the 2014 Annual Meeting, stockholders ratified the selection of Mayer Hoffman McCann, P.C. as the Company’s independent public accountants for the fiscal year ending December 31, 2014.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514198873/d726732d8k.htm,0.9
5/14/2014,8-K,sec_disclosure,corporate,"At the 2014 Annual Meeting, stockholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 300 million to 600 million shares.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514198873/d726732d8k.htm,0.9
5/13/2014,8-K,sec_disclosure,regulatory,"On May 13, 2014, International Stem Cell Corporation filed a Current Report on Form 8-K with the SEC pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514196086/d727521d8k.htm,0.9
5/13/2014,8-K,sec_disclosure,corporate,"On May 13, 2014, the Company issued a press release reporting its financial results for the first quarter ended March 31, 2014, which was furnished as Exhibit 99.1 to the Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514196086/d727521d8k.htm,0.9
3/18/2014,8-K,sec_disclosure,corporate,"On March 18, 2014, International Stem Cell Corporation issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514103465/d694599d8k.htm,0.9
3/17/2014,10-K,sec_disclosure,ip,"ISCO scientists created the first parthenogenetic, homozygous human stem cell line capable of providing immune-matched cells for a broad population.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514102696/d652768d10k.htm,0.9
3/17/2014,10-K,sec_disclosure,ip,The company’s UniStemCell collection grew to include fifteen human parthenogenetic stem cell (hpSC) lines.,https://www.sec.gov/Archives/edgar/data/1355790/000119312514102696/d652768d10k.htm,0.9
3/17/2014,10-K,sec_disclosure,regulatory,ISCO established facilities and manufacturing protocols that comply with FDA-enforced Good Manufacturing Practice (GMP) standards.,https://www.sec.gov/Archives/edgar/data/1355790/000119312514102696/d652768d10k.htm,0.9
3/17/2014,10-K,sec_disclosure,regulatory,The company anticipates filing an Investigational New Drug (IND) application with the FDA in late 2014 or early 2015 for its neural stem cell program.,https://www.sec.gov/Archives/edgar/data/1355790/000119312514102696/d652768d10k.htm,0.9
3/17/2014,10-K,sec_disclosure,clinical,"Upon FDA IND approval, ISCO plans to commence a Phase I clinical trial of its neural stem cell therapy in collaboration with Duke University.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514102696/d652768d10k.htm,0.9
3/17/2014,10-K,sec_disclosure,corporate,"In the years ended December 31, 2013 and 2012, ISCO generated $6.1 million and $4.6 million, respectively, from its two revenue-generating commercial businesses.",https://www.sec.gov/Archives/edgar/data/1355790/000119312514102696/d652768d10k.htm,0.9
12/11/2013,8-K,sec_disclosure,corporate,"On December 10, 2013, ISCC entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC under which LPC committed to purchase up to $10.25 million of ISCC common stock over 36 months, including an initial purchase of 1,666,666 shares for $250,000.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513469828/d644079d8k.htm,0.9
12/11/2013,8-K,sec_disclosure,corporate,"On December 10, 2013, ISCC entered into a Registration Rights Agreement with Lincoln Park Capital Fund, LLC under which ISCC agreed to file and maintain a Form S-1 registration statement for the resale of up to 20 million shares sold to LPC under the Purchase Agreement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513469828/d644079d8k.htm,0.9
12/11/2013,8-K,sec_disclosure,regulatory,"ISCC’s sales of Purchase Shares to Lincoln Park Capital Fund under the Purchase Agreement were exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, as disclosed in Item 3.02 of the Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513469828/d644079d8k.htm,0.9
12/11/2013,8-K,sec_disclosure,corporate,"On December 11, 2013, ISCC issued a press release (filed as Exhibit 99.1) announcing the execution of both the Purchase Agreement and the Registration Rights Agreement with Lincoln Park Capital Fund.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513469828/d644079d8k.htm,0.9
11/13/2013,8-K,sec_disclosure,corporate,"On November 13, 2013, International Stem Cell Corporation issued a press release reporting its financial results for the third quarter ended September 30, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513439431/d627942d8k.htm,0.9
11/13/2013,8-K,sec_disclosure,regulatory,"The Company furnished Exhibit 99.1 (the press release dated November 13, 2013) in its Form 8-K filing, satisfying the Exhibit requirements under Item 2.02 and Item 9.01.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513439431/d627942d8k.htm,0.9
9/19/2013,8-K,sec_disclosure,corporate,"On September 15, 2013, James H. Berglund notified International Stem Cell Corporation of his resignation from the Company’s Board of Directors, effective the same day, and did not cite any disagreement with the Company.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513371652/d601207d8k.htm,0.9
8/8/2013,8-K,sec_disclosure,corporate,"On August 8, 2013, International Stem Cell Corporation issued a press release reporting its financial results for the second quarter ended June 30, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513325376/d582119d8k.htm,0.9
7/19/2013,8-K,sec_disclosure,corporate,"On July 19, 2013, the Company entered into subscription agreements with certain investors for the sale and issuance of 20,000,000 Units (each consisting of one share of common stock and one Series A Warrant) and 20,000,000 Series B Warrants, for aggregate gross proceeds of $3,000,000 before fees and expenses.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513295042/d568571d8k.htm,0.9
7/19/2013,8-K,sec_disclosure,corporate,"On July 19, 2013, the Company entered into a Placement Agent Agreement with Roth Capital Partners, LLC, under which Roth agreed to use reasonable best efforts to market the Offering in exchange for a 5% cash fee, Placement Agent Warrants equal to 5% of the Units issued, and reimbursement of out-of-pocket expenses up to $75,000.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513295042/d568571d8k.htm,0.9
7/19/2013,8-K,sec_disclosure,regulatory,"On July 18, 2013, the Securities and Exchange Commission declared effective the Company’s registration statement on Form S-1 (File No. 333-184493), under which the Common Stock, Series A Warrants, Series B Warrants and Placement Agent Warrants are being issued.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513295042/d568571d8k.htm,0.9
7/19/2013,8-K,sec_disclosure,corporate,"On July 19, 2013, the Company issued a press release announcing the Offering, the terms of the Units and Warrants, and the involvement of the placement agent, which was filed as Exhibit 99.1 to this Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513295042/d568571d8k.htm,0.9
7/19/2013,8-K,sec_disclosure,corporate,"The Company expects the Offering to close on July 24, 2013, subject to customary closing conditions, at which time it will deliver the Units, Series A Warrants and Series B Warrants to the investors.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513295042/d568571d8k.htm,0.9
6/13/2013,8-K,sec_disclosure,corporate,"International Stem Cell Corporation held its Annual Meeting of Stockholders on June 10, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513257926/d553591d8k.htm,0.9
6/13/2013,8-K,sec_disclosure,corporate,"At the meeting, stockholders elected six directors to hold office until the 2014 Annual Meeting.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513257926/d553591d8k.htm,0.9
6/13/2013,8-K,sec_disclosure,corporate,"Stockholders ratified the selection of Mayer Hoffman McCann, P.C., as the Company’s independent public accountants for the fiscal year ending December 31, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513257926/d553591d8k.htm,0.9
6/13/2013,8-K,sec_disclosure,corporate,"On an advisory basis, stockholders approved the compensation of the Company’s named executive officers as disclosed in the proxy statement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513257926/d553591d8k.htm,0.9
6/13/2013,8-K,sec_disclosure,corporate,"On an advisory basis, stockholders indicated they prefer to hold future advisory votes on executive compensation every two years, and the Board determined to adopt a biennial frequency.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513257926/d553591d8k.htm,0.9
5/14/2013,8-K,sec_disclosure,corporate,"On May 14, 2013, International Stem Cell Corporation issued a press release reporting its financial results for the first quarter ended March 31, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513218236/d538866d8k.htm,0.9
5/14/2013,8-K,sec_disclosure,regulatory,"On May 14, 2013, the Company filed a Form 8-K with the SEC, including Exhibit 99.1 (the press release), to furnish its current report pursuant to Item 2.02 and Item 9.01.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513218236/d538866d8k.htm,0.9
5/14/2013,10-Q,sec_disclosure,corporate,"International Stem Cell Corporation filed its Quarterly Report on Form 10-Q with the SEC for the quarter ended March 31, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513217562/d501284d10q.htm,0.9
5/14/2013,10-Q,sec_disclosure,corporate,The registrant affirmed that it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such requirements for the past 90 days.,https://www.sec.gov/Archives/edgar/data/1355790/000119312513217562/d501284d10q.htm,0.9
5/14/2013,10-Q,sec_disclosure,corporate,The company indicated that it has submitted and posted every required Interactive Data File on its corporate website pursuant to Rule 405 of Regulation S-T over the preceding 12 months.,https://www.sec.gov/Archives/edgar/data/1355790/000119312513217562/d501284d10q.htm,0.9
5/14/2013,10-Q,sec_disclosure,corporate,International Stem Cell Corporation indicated its status as a smaller reporting company in its Form 10-Q.,https://www.sec.gov/Archives/edgar/data/1355790/000119312513217562/d501284d10q.htm,0.9
5/14/2013,10-Q,sec_disclosure,corporate,The registrant confirmed that it is not a shell company as defined in Rule 12b-2 of the Securities Exchange Act of 1934.,https://www.sec.gov/Archives/edgar/data/1355790/000119312513217562/d501284d10q.htm,0.9
5/14/2013,10-Q,sec_disclosure,corporate,"The number of shares of the company’s common stock outstanding was reported as 112,363,815 as of May 3, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513217562/d501284d10q.htm,0.9
4/15/2013,8-K,sec_disclosure,corporate,"Ms. Linh Nguyen notified the Board of her resignation as Chief Financial Officer, effective April 15, 2013, and agreed to assist with the transition of her responsibilities.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513155076/d521541d8k.htm,0.9
4/15/2013,8-K,sec_disclosure,corporate,"Mr. Jay Novak, previously Director of Finance, was appointed interim Chief Financial Officer effective April 16, 2013.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513155076/d521541d8k.htm,0.9
4/15/2013,8-K,sec_disclosure,corporate,"In January 2013, holders of all shares of Series C Preferred Stock converted their shares into common stock, leaving no Series C Preferred Stock outstanding.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513155076/d521541d8k.htm,0.9
4/15/2013,8-K,sec_disclosure,corporate,"On April 10, 2013, the Company filed a Certificate of Elimination to amend its Certificate of Incorporation and eliminate all rights and preferences associated with the Series C Preferred Stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513155076/d521541d8k.htm,0.9
3/27/2013,8-K,sec_disclosure,regulatory,"On March 27, 2013, the Company filed a Current Report on Form 8-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 to report certain corporate events.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513128037/d511103d8k.htm,0.9
3/27/2013,8-K,sec_disclosure,corporate,"On March 27, 2013, International Stem Cell Corporation issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513128037/d511103d8k.htm,0.9
3/27/2013,8-K,sec_disclosure,regulatory,"The press release dated March 27, 2013 was furnished as Exhibit 99.1 under Item 2.02 of the Form 8-K, and is not deemed ‘‘filed’’ under the Exchange Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513128037/d511103d8k.htm,0.9
2/14/2013,8-K,sec_disclosure,corporate,"On February 7, 2013, International Stem Cell Corporation entered into Amended and Restated License Agreements with Advanced Cell Technology, Inc. to completely amend and restate the terms of three Exclusive License Agreements originally executed in 2005.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513055840/d486914d8k.htm,0.9
2/14/2013,8-K,sec_disclosure,ip,"Under the Amendment, the Company acquired exclusive worldwide rights to all human therapeutic and cosmetic uses of parthenogenic-derived embryonic stem cells from ACT and Infigen, as well as certain patent rights covering Single Blastomere technology.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513055840/d486914d8k.htm,0.9
2/14/2013,8-K,sec_disclosure,ip,"Pursuant to the Amendment, all minimum research and development requirements and all milestone payments previously due to ACT under the Exclusive License Agreements have been eliminated.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513055840/d486914d8k.htm,0.9
2/14/2013,8-K,sec_disclosure,ip,The Amendment also eliminates royalty payments under the ACT IP and Infigen IP Agreements and reduces the royalty rate under the UMass IP Agreement from 6%–12% of net sales to 0.25%.,https://www.sec.gov/Archives/edgar/data/1355790/000119312513055840/d486914d8k.htm,0.9
1/24/2013,8-K,sec_disclosure,corporate,"On January 22, 2013, the Company entered into a Securities Purchase Agreement with two executive officers to sell 10,125,000 shares of common stock at $0.20 per share for $2,025,000, and issued warrants exercisable for five years to purchase up to 5,062,500 additional shares at $0.20 per share in a private placement exempt from registration under Section 4(2) and Rule 506 of the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513021379/d472726d8k.htm,0.9
1/24/2013,8-K,sec_disclosure,corporate,"Immediately prior to the above sale, the Company issued 8,000,000 shares of common stock upon conversion of all outstanding Series C Preferred Stock at the existing conversion rate in a transaction exempt from registration under Section 3(a)(9) of the Securities Act.",https://www.sec.gov/Archives/edgar/data/1355790/000119312513021379/d472726d8k.htm,0.9
12/5/2012,8-K,sec_disclosure,regulatory,"Filed a Form 8-K current report with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 on December 4, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512491034/d449242d8k.htm,0.9
12/5/2012,8-K,sec_disclosure,corporate,"Mr. Jeffrey Janus resigned from his position as Senior Vice President of International Stem Cell Corporation effective November 30, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512491034/d449242d8k.htm,0.9
12/5/2012,8-K,sec_disclosure,corporate,"On March 9, 2012, the Company entered into a five-year consulting services agreement with Mr. Janus to allow continued access to his historical knowledge and experience.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512491034/d449242d8k.htm,0.9
12/5/2012,8-K,sec_disclosure,corporate,"Beginning December 17, 2012, Mr. Janus is expected to provide consulting services to the Company under the terms of the existing consulting agreement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512491034/d449242d8k.htm,0.9
11/9/2012,8-K,sec_disclosure,regulatory,"International Stem Cell Corporation filed a Form 8-K on November 9, 2012, reporting its third quarter financial results for the period ended September 30, 2012, pursuant to Sections 13 and 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512463513/d437492d8k.htm,0.9
11/9/2012,8-K,sec_disclosure,corporate,"The Company issued a press release on November 9, 2012, to announce its financial results for the third quarter ended September 30, 2012, which was furnished as Exhibit 99.1 to the Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512463513/d437492d8k.htm,0.9
8/9/2012,8-K,sec_disclosure,corporate,"On August 9, 2012, International Stem Cell Corporation issued a press release reporting its financial results for the second quarter ended June 30, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512345686/d394238d8k.htm,0.9
8/9/2012,8-K,sec_disclosure,regulatory,"The company filed a Current Report on Form 8-K with the SEC on August 9, 2012, furnishing Exhibit 99.1 under Item 2.02 and Item 9.01 in compliance with Section 13 or 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512345686/d394238d8k.htm,0.9
8/3/2012,8-K,sec_disclosure,corporate,"On August 1, 2012, Jeffrey Janus resigned from International Stem Cell Corporation’s Board of Directors while continuing his employment as Senior Vice President of Operations.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512334909/d392085d8k.htm,0.9
6/4/2012,8-K,sec_disclosure,corporate,"On May 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to increase the number of authorized common stock shares from 200,000,000 to 300,000,000.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512257533/d360055d8k.htm,0.9
6/4/2012,8-K,sec_disclosure,corporate,"Following conversion by holders of all outstanding Series A Preferred Stock into common stock, there were no remaining shares of Series A Preferred Stock outstanding.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512257533/d360055d8k.htm,0.9
6/4/2012,8-K,sec_disclosure,corporate,"On May 30, 2012, the Company filed a Certificate of Elimination to remove all powers, designations, preferences, privileges, and other rights of the Series A Preferred Stock from its Certificate of Incorporation.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512257533/d360055d8k.htm,0.9
6/4/2012,8-K,sec_disclosure,corporate,"The Company held its 2012 Annual Meeting of Stockholders on May 29, 2012, at which matters including director elections and charter amendments were submitted for shareholder vote.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512257533/d360055d8k.htm,0.9
6/4/2012,8-K,sec_disclosure,corporate,"Proposal 1 at the Annual Meeting: Stockholders elected seven directors to hold office until the 2012 Annual Meeting, including two by Series C and D Preferred holders and five by all stockholders.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512257533/d360055d8k.htm,0.9
6/4/2012,8-K,sec_disclosure,corporate,"Proposal 2 at the Annual Meeting: Stockholders ratified the selection of Mayer Hoffman McCann, P.C. as the Company’s independent public accountants for the fiscal year ending December 31, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512257533/d360055d8k.htm,0.9
6/4/2012,8-K,sec_disclosure,corporate,Proposal 3 at the Annual Meeting: Stockholders approved an amendment to the Company’s Certificate of Incorporation to increase authorized common stock shares from 200 million to 300 million.,https://www.sec.gov/Archives/edgar/data/1355790/000119312512257533/d360055d8k.htm,0.9
5/14/2012,10-Q,sec_disclosure,regulatory,"Filed a Quarterly Report on Form 10-Q with the SEC for the period ended March 31, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512231204/d336986d10q.htm,0.9
5/14/2012,10-Q,sec_disclosure,regulatory,"Affirmed compliance with all Exchange Act filing requirements for the prior 12 months, submitted Interactive Data Files under Regulation S-T Rule 405, and confirmed its status as an accelerated filer and not a shell company.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512231204/d336986d10q.htm,0.9
5/14/2012,10-Q,sec_disclosure,corporate,"Issued 5,000,000 shares of Convertible Redeemable Series G Preferred Stock with a $5.018 million liquidation preference as of March 31, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512231204/d336986d10q.htm,0.9
5/14/2012,10-Q,sec_disclosure,corporate,"Recorded a settlement with a related company, reflecting the adjustment in other income (expense) in the quarter.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512231204/d336986d10q.htm,0.9
5/14/2012,10-Q,sec_disclosure,corporate,"Reported 87,036,315 shares of Common Stock outstanding as of May 4, 2012.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512231204/d336986d10q.htm,0.9
4/18/2012,8-K,sec_disclosure,corporate,"On April 17, 2012, the Company issued an additional 2,000,000 shares of common stock upon conversion of all remaining Series A Preferred Stock in transactions exempt from registration under Section 3(a)(9) of the Securities Act, bringing total common shares outstanding to 87,036,315.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512168016/d336701d8k.htm,0.9
3/28/2012,8-K,sec_disclosure,corporate,"On March 22, 2012, the Board of Directors eliminated the separate position of President and Chief Operating Officer and assigned those responsibilities to CEO Dr. Andrey Semechkin.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512136869/d325771d8k.htm,0.9
3/28/2012,8-K,sec_disclosure,corporate,"Former President and COO Kurt May will remain with the Company through April 3, 2012 to assist with the transition and will receive a severance payment equal to two months of his annual base salary upon departure.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512136869/d325771d8k.htm,0.9
3/22/2012,8-K,sec_disclosure,corporate,"On March 20, 2012, International Stem Cell Corporation issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2011.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512127081/d320783d8k.htm,0.9
3/22/2012,8-K,sec_disclosure,regulatory,"On March 20, 2012, the company filed a Form 8-K Current Report pursuant to Sections 13 and 15(d) of the Exchange Act, furnishing the press release as Exhibit 99.1.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512127081/d320783d8k.htm,0.9
3/16/2012,10-K,sec_disclosure,corporate,"International Stem Cell Corporation filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2011 with the SEC.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512119981/d270049d10k.htm,0.9
3/16/2012,10-K,sec_disclosure,corporate,"The company transitioned from a smaller reporting company to an accelerated filer under SEC rules effective December 31, 2011.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512119981/d270049d10k.htm,0.9
3/16/2012,10-K,sec_disclosure,regulatory,ISCO’s manufacturing facilities and protocols achieved compliance with U.S. Food and Drug Administration and other regulatory authorities’ requirements.,https://www.sec.gov/Archives/edgar/data/1355790/000119312512119981/d270049d10k.htm,0.9
3/16/2012,10-K,sec_disclosure,corporate,ISCO’s definitive Proxy Statement for its 2012 Annual Meeting of Stockholders is incorporated by reference into Part III of this Form 10-K.,https://www.sec.gov/Archives/edgar/data/1355790/000119312512119981/d270049d10k.htm,0.9
3/6/2012,8-K,sec_disclosure,corporate,"From January 23, 2012 through February 29, 2012, the Company issued one million shares of its common stock to Aspire Capital Fund, LLC for total consideration of $400,670 in private placement transactions.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512099307/d311973d8k.htm,0.9
3/6/2012,8-K,sec_disclosure,regulatory,The private placement transactions were made in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act of 1933.,https://www.sec.gov/Archives/edgar/data/1355790/000119312512099307/d311973d8k.htm,0.9
1/18/2012,8-K,sec_disclosure,corporate,"From November 11, 2011 through January 16, 2012, the Company issued a total of one million shares of common stock to Aspire Capital Fund, LLC in private placement transactions for aggregate proceeds of $416,010. The shares were sold in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933.",https://www.sec.gov/Archives/edgar/data/1355790/000119312512014286/d284650d8k.htm,0.9
10/12/2011,8-K,sec_disclosure,corporate,"On October 5, 2011, the Board of Directors promoted Dr. Andrey Semechkin from Chief Executive Officer and President to Co-Chairman, to serve alongside Kenneth Aldrich while retaining his CEO role.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511269177/d242699d8k.htm,0.9
10/12/2011,8-K,sec_disclosure,corporate,"On October 5, 2011, the Board of Directors appointed Kurt May, formerly Senior Vice President, as President and Chief Operating Officer of the Company.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511269177/d242699d8k.htm,0.9
9/27/2011,8-K,sec_disclosure,corporate,"Effective September 30, 2011, Ray Wood’s employment as Chief Financial Officer was terminated.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511257564/d237275d8k.htm,0.9
9/27/2011,8-K,sec_disclosure,corporate,"Effective October 3, 2011, Linh Nguyen was appointed as the new Chief Financial Officer of the company.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511257564/d237275d8k.htm,0.9
9/27/2011,8-K,sec_disclosure,corporate,"Under the terms of her employment, Linh Nguyen will receive an annual salary of $160,000, standard employee benefits including medical and dental insurance, and may be granted stock options by the Board.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511257564/d237275d8k.htm,0.9
9/27/2011,8-K,sec_disclosure,regulatory,The company filed Exhibit 10.1 – the Employment Offer Letter with Linh Nguyen – under Item 9.01 of the Form 8-K.,https://www.sec.gov/Archives/edgar/data/1355790/000119312511257564/d237275d8k.htm,0.9
8/15/2011,8-K,sec_disclosure,regulatory,"On August 15, 2011, the Audit Committee determined that the Company’s financial statements for the quarter ended March 31, 2011 should no longer be relied upon due to an understatement of accrued marketing expenses.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511223009/d8k.htm,0.9
8/15/2011,8-K,sec_disclosure,regulatory,"The Company plans to restate its financial statements for the quarter ended March 31, 2011 by amending the Form 10-Q and to file the quarterly Report on Form 10-Q for the quarter ended June 30, 2011 shortly thereafter.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511223009/d8k.htm,0.9
8/15/2011,8-K,sec_disclosure,corporate,"In late 2010, the Company signed a Term Sheet with a third-party marketing organization under which Lifeline Skin Care, LLC would pay 40% of net profits during a test phase to market its products to proprietary mailing lists.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511223009/d8k.htm,0.9
8/15/2011,8-K,sec_disclosure,corporate,"As a result of its review, the Company identified and corrected $154,983 of marketing expenses that were not accrued in the first quarter of 2011.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511223009/d8k.htm,0.9
8/15/2011,8-K,sec_disclosure,corporate,The Company is enhancing its internal controls and procedures and has provided additional information regarding these measures in the amended Form 10-Q filed concurrently with this Form 8-K.,https://www.sec.gov/Archives/edgar/data/1355790/000119312511223009/d8k.htm,0.9
6/23/2011,10-Q,sec_disclosure,regulatory,"The Company filed an amended Annual Report on Form 10-K/A for the year ended December 31, 2010 to correct previously issued financial statements.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
6/23/2011,10-Q,sec_disclosure,corporate,"The Company concluded on May 25, 2011 that its financial statements for the periods through September 30, 2010 were unreliable and restated the audited and quarterly financials due to incorrect accounting for certain warrants.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
6/23/2011,10-Q,sec_disclosure,regulatory,"As of January 1, 2009, the Company adopted FASB ASC 815-40 (formerly EITF 07-5) governing equity versus liability classification for equity-linked instruments but failed to apply it properly to certain anti-dilution warrant provisions.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
6/23/2011,10-Q,sec_disclosure,corporate,"In early 2009, the Company issued Series D Preferred Stock carrying a cumulative 10% dividend, payable quarterly, which it originally recorded only when paid.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
6/23/2011,10-Q,sec_disclosure,corporate,"The Company changed its accounting policy to accrue the 10% quarterly dividends on Series D Preferred Stock, prompting restatement of its 2009 and 2010 financial statements.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
6/23/2011,10-Q,sec_disclosure,corporate,"In this Form 10-Q for the quarter ended March 31, 2011, the Company restated the comparative 2010 period results to reflect the warrant accounting and dividend accrual corrections.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
6/23/2011,10-Q,sec_disclosure,corporate,"As of June 17, 2011, International Stem Cell Corporation had 76,299,928 shares of common stock outstanding.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
6/23/2011,10-Q,sec_disclosure,corporate,The registrant confirmed it qualifies as a smaller reporting company and is not a shell company under SEC rules.,https://www.sec.gov/Archives/edgar/data/1355790/000119312511171871/d10q.htm,0.9
5/31/2011,8-K,sec_disclosure,regulatory,"On May 25, 2011, the Audit Committee determined that the Company’s financial statements for the years ended December 31, 2009 and 2010 and the quarterly periods in those years should no longer be relied upon due to errors in accounting for anti-dilution warrants.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511154929/d8k.htm,0.9
5/31/2011,8-K,sec_disclosure,regulatory,"The Company announced plans to restate its financial statements for the affected periods and to amend its Form 10-K for the year ended December 31, 2010 once the accounting issues are resolved.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511154929/d8k.htm,0.9
5/31/2011,8-K,sec_disclosure,regulatory,"During review in Q1 2011, the Company adopted EITF Issue 07-5 (ASC 815-40-15) guidance requiring that warrants with anti-dilution features be classified as liabilities and re-measured at fair value each reporting period.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511154929/d8k.htm,0.9
5/31/2011,8-K,sec_disclosure,corporate,"The restatement will reclassify the previously issued warrants from equity to liabilities measured at fair value using the Black-Scholes model and will have no impact on assets, revenues, operating expenses, cash flows, or accounts payable.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511154929/d8k.htm,0.9
5/31/2011,8-K,sec_disclosure,corporate,"The Company expects that by the first quarter of 2012 all of the warrants will have been exercised or expired, and the resulting noncash gains or losses will be reflected equally in accumulated deficit and additional paid-in capital.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511154929/d8k.htm,0.9
5/31/2011,8-K,sec_disclosure,corporate,The Audit Committee discussed the accounting and restatement matters described in Item 4.02 with the Company’s independent registered public accounting firm.,https://www.sec.gov/Archives/edgar/data/1355790/000119312511154929/d8k.htm,0.9
5/25/2011,8-K,sec_disclosure,corporate,"On May 25, 2011, International Stem Cell Corporation issued a press release reporting its financial results for the first quarter ended March 31, 2011.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511150285/d8k.htm,0.9
5/25/2011,8-K,sec_disclosure,regulatory,"International Stem Cell Corporation filed a Form 8-K on May 25, 2011, furnishing the press release as Exhibit 99.1 in accordance with SEC Item 2.02 and Item 9.01 requirements.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511150285/d8k.htm,0.9
5/13/2011,8-K,sec_disclosure,corporate,"Effective May 11, 2011, the Company entered into an amended and restated employment arrangement with Brian Lundstrom, under which he will receive a $250,000 annual salary, standard employee benefits, and has relinquished rights to unvested options for 1,980,000 shares of common stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511139689/d8k.htm,0.9
5/13/2011,8-K,sec_disclosure,corporate,Brian Lundstrom ceased to be an executive officer of the Company and will focus on international business development projects.,https://www.sec.gov/Archives/edgar/data/1355790/000119312511139689/d8k.htm,0.9
5/13/2011,8-K,sec_disclosure,corporate,"Dr. Andrey Semechkin, previously Chief Executive Officer, assumed the additional responsibilities and title of President without any changes to his existing employment agreement.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511139689/d8k.htm,0.9
5/6/2011,8-K,sec_disclosure,corporate,"On May 3, 2011, International Stem Cell Corporation’s Board of Directors adopted Amended and Restated Bylaws, updating provisions to reflect changes in Delaware law and corporate governance practices since 2006.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511130033/d8k.htm,0.9
5/6/2011,8-K,sec_disclosure,corporate,"The Company held its Annual Meeting of Stockholders on May 3, 2011, where various corporate governance and financial matters were presented for a shareholder vote.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511130033/d8k.htm,0.9
5/6/2011,8-K,sec_disclosure,corporate,"At the Annual Meeting, stockholders elected seven directors to serve until the 2011 Annual Meeting of Stockholders, with all nominees receiving the requisite votes for election.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511130033/d8k.htm,0.9
5/6/2011,8-K,sec_disclosure,corporate,"Also at the Annual Meeting, stockholders ratified the selection of Mayer Hoffman McCann, P.C. as the Company’s independent public accountants for the fiscal year ending December 31, 2011.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511130033/d8k.htm,0.9
3/29/2011,8-K,sec_disclosure,corporate,"On March 25, 2011, the Audit Committee approved and the Company dismissed Vasquez & Company, LLP as its independent registered public accounting firm.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511081260/d8k.htm,0.9
3/29/2011,8-K,sec_disclosure,corporate,"On March 25, 2011, the Audit Committee approved and the Company engaged Mayer Hoffman McCann P.C. as its new independent registered public accounting firm.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511081260/d8k.htm,0.9
3/16/2011,8-K,sec_disclosure,regulatory,"International Stem Cell Corporation filed a Form 8-K on March 16, 2011 to report the furnishing of presentation slides as an exhibit.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511068360/d8k.htm,0.9
3/16/2011,8-K,sec_disclosure,corporate,"The company provided a copy of slides used in presentations to investors, analysts, stockholders and other interested parties.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511068360/d8k.htm,0.9
2/28/2011,8-K,sec_disclosure,corporate,"The Company entered into a lease agreement with S Real Estate Holding LLC for approximately 4,653 square feet of new office space at 5950 Priestly Drive, Carlsbad, California, effective March 1, 2011, with a term through February 29, 2016 and an option to extend for up to five additional years.",https://www.sec.gov/Archives/edgar/data/1355790/000119312511049857/d8k.htm,0.9
12/13/2010,8-K,sec_disclosure,corporate,"On December 9, 2010, International Stem Cell Corporation entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC, under which Aspire Capital is committed to purchase up to $25 million of ISCC common stock over three years and ISCC sold an initial 333,333 shares for $500,000 and granted a 500,000-share commitment fee.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510278552/d8k.htm,0.9
12/13/2010,8-K,sec_disclosure,corporate,"On December 9, 2010, ISCC also entered into a Registration Rights Agreement with Aspire Capital to register the resale of the commitment-fee shares and any shares sold under the Purchase Agreement, and to keep the registration statement effective while indemnifying Aspire Capital for certain liabilities.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510278552/d8k.htm,0.9
9/15/2010,8-K,sec_disclosure,regulatory,"International Stem Cell Corporation filed a Form 8-K current report with the SEC on September 15, 2010, fulfilling its disclosure obligations under Section 13 or 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510210396/d8k.htm,0.9
9/15/2010,8-K,sec_disclosure,corporate,"The company provided a copy of the slides used in presentations to investors, analysts, stockholders and other interested parties, which were attached as Exhibit 99.1 to the Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510210396/d8k.htm,0.9
8/5/2010,8-K,sec_disclosure,corporate,"In June 2010, International Stem Cell Corporation retired all previously outstanding shares of Series E Preferred Stock and Series F Preferred Stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510179040/d8k.htm,0.9
8/5/2010,8-K,sec_disclosure,corporate,"On August 4, 2010, the Company filed Certificates of Elimination with the Delaware Secretary of State to amend its Certificate of Incorporation by eliminating the powers, designations, preferences, privileges and other rights of the Series E and Series F Preferred Stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510179040/d8k.htm,0.9
6/22/2010,8-K,sec_disclosure,corporate,"On June 21, 2010, International Stem Cell Corporation’s Board of Directors elected Charles J. Casamento to serve as a non-employee director until the 2011 annual meeting, with customary cash retainer and stock option grant compensation.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510143798/d8k.htm,0.9
6/14/2010,8-K,sec_disclosure,corporate,"On June 11, 2010, International Stem Cell Corporation entered into an exchange agreement with Socius CG II, Ltd., under which the Company exchanged all Series F Preferred Stock for Socius promissory notes and each party waived accrued interest, dividends, and redemption premiums.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510138839/d8k.htm,0.9
6/14/2010,8-K,sec_disclosure,corporate,"On June 11, 2010, International Stem Cell Corporation entered into an exchange agreement with Optimus Capital Partners, LLC, under which the Company exchanged all Series E Preferred Stock for Optimus promissory notes and each party waived accrued interest, dividends, and redemption premiums.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510138839/d8k.htm,0.9
6/14/2010,8-K,sec_disclosure,corporate,"As a result of these exchange transactions, all of the Company’s obligations under the outstanding Series E and Series F Preferred Stock were retired, and the Company no longer holds any promissory notes of either Socius or Optimus.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510138839/d8k.htm,0.9
5/19/2010,8-K,sec_disclosure,corporate,"International Stem Cell Corporation entered into a Cell Culture Automation Agreement with The Automation Partnership on May 13, 2010 to automate and scale up production of stem cell-derived human corneal tissue, with estimated project costs of approximately $1.5 million.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510123568/d8k.htm,0.9
5/5/2010,8-K,sec_disclosure,corporate,"On May 4, 2010, International Stem Cell Corporation entered into a Preferred Stock Purchase Agreement with Socius CG II, Ltd. to sell up to 1,000 shares of Series F Preferred Stock for up to $10 million, including the issuance of 250,000 non-refundable fee shares and a warrant to purchase up to $13.5 million of common stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510107620/d8k.htm,0.9
5/5/2010,8-K,sec_disclosure,corporate,"Also on May 4, 2010, the Company amended its Certificate of Incorporation by filing a Certificate of Designation to create the Series F Preferred Stock, setting its dividend rate, redemption rights and limitations on conversion.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510107620/d8k.htm,0.9
5/3/2010,8-K,sec_disclosure,corporate,"Annual Meeting of Stockholders held on April 28, 2010, at which three proposals were considered by stockholders.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510103869/d8k.htm,0.9
5/3/2010,8-K,sec_disclosure,corporate,"Election of six directors to hold office until the 2011 Annual Meeting, with votes cast by holders of various series of preferred and common stock.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510103869/d8k.htm,0.9
5/3/2010,8-K,sec_disclosure,corporate,"Ratification of the selection of Vasquez & Company LLP as International Stem Cell Corporation’s independent public accountants for the fiscal year ending December 31, 2010.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510103869/d8k.htm,0.9
5/3/2010,8-K,sec_disclosure,corporate,Approval by stockholders of the 2010 Equity Participation Plan.,https://www.sec.gov/Archives/edgar/data/1355790/000119312510103869/d8k.htm,0.9
3/23/2010,10-K,sec_disclosure,clinical,Initiation of the UniStemCell™ Bank project to build a repository of clinical-grade human stem cells immune-matched to large population segments.,https://www.sec.gov/Archives/edgar/data/1355790/000119312510064413/d10k.htm,0.9
3/23/2010,10-K,sec_disclosure,clinical,Development of a new class of pluripotent stem cells with a derivation process distinct from embryonic stem cells that avoids the use of fertilized eggs or destruction of viable embryos.,https://www.sec.gov/Archives/edgar/data/1355790/000119312510064413/d10k.htm,0.9
3/23/2010,10-K,sec_disclosure,clinical,Research and development of protocols to differentiate pluripotent stem cells into specific cell types needed for transplantation therapies.,https://www.sec.gov/Archives/edgar/data/1355790/000119312510064413/d10k.htm,0.9
3/23/2010,10-K,sec_disclosure,regulatory,Establishment of facilities and manufacturing protocols to produce stem cells without animal by-products in compliance with FDA and other regulatory authorities' requirements.,https://www.sec.gov/Archives/edgar/data/1355790/000119312510064413/d10k.htm,0.9
3/23/2010,10-K,sec_disclosure,corporate,"Formation of Lifeline Cell Technology (LCT) as a wholly-owned subsidiary to create, manufacture, and sell research products for culturing human cells.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510064413/d10k.htm,0.9
3/23/2010,10-K,sec_disclosure,corporate,"Formation of Lifeline Skin Care (LSC) as a wholly-owned subsidiary to develop, manufacture, and distribute cosmetic skin care products derived from company human cell technologies.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510064413/d10k.htm,0.9
2/3/2010,8-K,sec_disclosure,corporate,"Issued 260,000 shares of common stock to two investor and public relations firms in exchange for services in private placement transactions.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510020837/d8k.htm,0.9
2/3/2010,8-K,sec_disclosure,corporate,"Issued 4,546,645 shares of common stock for total consideration of $2,500,000 upon exercises of warrants held by one investor.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510020837/d8k.htm,0.9
2/3/2010,8-K,sec_disclosure,corporate,"Issued 1,755,022 shares of common stock upon conversion of previously issued shares of preferred stock or warrants held by five investors.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510020837/d8k.htm,0.9
2/3/2010,8-K,sec_disclosure,corporate,"Issued 83,333 shares of common stock for total consideration of $75,000 from a stock purchase by one accredited investor.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510020837/d8k.htm,0.9
2/3/2010,8-K,sec_disclosure,regulatory,"Sold shares in clauses (i), (ii), and (iv) in private placements relying on exemptions from registration under Section 4(2) of the Securities Act of 1933.",https://www.sec.gov/Archives/edgar/data/1355790/000119312510020837/d8k.htm,0.9
2/3/2010,8-K,sec_disclosure,regulatory,Sold shares in clause (iii) in exchange for previously issued securities exempt from registration under Section 3(a)(9) of the Securities Act of 1933.,https://www.sec.gov/Archives/edgar/data/1355790/000119312510020837/d8k.htm,0.9
7/6/2009,8-K,sec_disclosure,corporate,"International Stem Cell Corporation appointed Professor Andrei Semetchkine, Ph.D., as its Executive Vice President to strengthen its senior management team.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709002421/isco_8k-063009.htm,0.9
7/6/2009,8-K,sec_disclosure,corporate,"Jeffrey Janus will continue as CEO and President of Lifeline Cell Technology and will also serve as Senior Vice President of Operations for the parent company, ISCO.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709002421/isco_8k-063009.htm,0.9
7/6/2009,8-K,sec_disclosure,corporate,"William Adams stepped down as acting Chief Financial Officer and resigned from the Board of Directors, effective June 30, 2009.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709002421/isco_8k-063009.htm,0.9
7/6/2009,8-K,sec_disclosure,corporate,"Ray Wood was promoted from controller to Vice President, Finance and Principal Financial Officer.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709002421/isco_8k-063009.htm,0.9
7/6/2009,8-K,sec_disclosure,corporate,"On June 30, 2009, the Company entered into a Preferred Stock Purchase Agreement with a biotechnology-focused fund to raise up to $5.0 million through the sale of up to 500 shares of newly authorized, non-convertible Series E Preferred Stock at $10,000 per share, payable in multiple tranches, and to issue warrants for 6,750,000 common shares plus a non-refundable $250,000 fee in common stock.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709002403/internationalstem_8k-063009.htm,0.9
7/6/2009,8-K,sec_disclosure,regulatory,"The Series E Preferred Stock and associated warrants were sold in a private placement exempt from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D, with the investor certified as an accredited investor under Rule 501.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709002403/internationalstem_8k-063009.htm,0.9
7/6/2009,8-K,sec_disclosure,corporate,"Also on June 30, 2009, the Company amended its Certificate of Incorporation by filing a Certificate of Designation to create the Series E Preferred Stock, specifying its liquidation preference, 10% per annum dividend accrual, and redemption rights with a declining premium over a four-year period.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709002403/internationalstem_8k-063009.htm,0.9
5/15/2009,10-Q,sec_disclosure,corporate,"On December 28, 2006, BTHC III, Inc. completed a share exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation (ISC California), resulting in a reverse merger for accounting purposes.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709001828/isco_10q-033109.htm,0.9
5/15/2009,10-Q,sec_disclosure,corporate,"On January 29, 2007, BTHC III, Inc. formally changed its corporate name to International Stem Cell Corporation.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709001828/isco_10q-033109.htm,0.9
5/15/2009,10-Q,sec_disclosure,corporate,"Lifeline Cell Technology, LLC was formed in California on August 17, 2001, to develop and manufacture human cell products.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709001828/isco_10q-033109.htm,0.9
5/15/2009,10-Q,sec_disclosure,ip,"During the three months ended March 31, 2009, the company made payments for patent licenses and trademarks as part of its ongoing intellectual property licensing activities.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709001828/isco_10q-033109.htm,0.9
3/30/2009,10-K,sec_disclosure,regulatory,"Filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2008 with the SEC.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709001101/isco_10k-123108.htm,0.9
3/30/2009,10-K,sec_disclosure,corporate,Incorporated by reference into Part III of the Form 10-K information from the definitive Proxy Statement for the 2009 Annual Meeting of Stockholders.,https://www.sec.gov/Archives/edgar/data/1355790/000101968709001101/isco_10k-123108.htm,0.9
3/30/2009,10-K,sec_disclosure,ip,Published two peer-reviewed papers in 2007 and 2008 describing its procedures for creating pluripotent stem cells through parthenogenesis.,https://www.sec.gov/Archives/edgar/data/1355790/000101968709001101/isco_10k-123108.htm,0.9
3/18/2009,8-K,sec_disclosure,corporate,"On December 29, 2008, the Company issued 2,121,180 shares of common stock to seven executive officers and directors under time-based vesting and restriction provisions, as compensation for reduced cash compensation in 2008.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709000891/isco_8k-031709.htm,0.9
3/18/2009,8-K,sec_disclosure,corporate,"Between January 28, 2009 and March 16, 2009, the holder of the OID Senior Secured Convertible Note converted $400,000 of principal into 1,600,000 shares of common stock at a $0.25 conversion price pursuant to an anti-dilution clause.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709000891/isco_8k-031709.htm,0.9
3/18/2009,8-K,sec_disclosure,corporate,"On March 16, 2008, the Company issued 10 shares of Series D Convertible Preferred Stock under the Series D Preferred Stock Purchase Agreement for a $1.0 million purchase price.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709000891/isco_8k-031709.htm,0.9
2/6/2009,8-K,sec_disclosure,corporate,"International Stem Cell Corporation entered into an Extension Agreement with Gemini Master Fund Ltd. on January 30, 2009, extending the due date for the remaining $400,000 balance of its promissory note from January 31, 2009 to April 5, 2009.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709000405/isco_8k-020309.htm,0.9
2/6/2009,8-K,sec_disclosure,corporate,"Under an Escrow Agreement dated February 3, 2009, the company deposited the $400,000 note balance into an interest-bearing escrow account, to be released to the lender on April 5, 2009 if not converted to common stock, with converted amounts released to the company.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709000405/isco_8k-020309.htm,0.9
2/6/2009,8-K,sec_disclosure,corporate,"Prior to the extension, the company repaid $500,000 of the original $1,000,000 promissory note and Gemini Master Fund Ltd. converted $100,000 of the note into common stock and released all liens against the company’s assets.",https://www.sec.gov/Archives/edgar/data/1355790/000101968709000405/isco_8k-020309.htm,0.9
10/16/2008,8-K,sec_disclosure,corporate,"On October 14, 2008, the Board of Directors of International Stem Cell Corporation elected Mr. Rouslan Semechkin to its Board pursuant to the terms of the August 20, 2008 Securities Purchase Agreement.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708004563/isco_8k-101608.htm,0.9
10/16/2008,8-K,sec_disclosure,corporate,"The company completed the sale of Series C Preferred Stock to X Master, Inc. under a Securities Purchase Agreement dated August 20, 2008, in which Mr. Semechkin serves as President.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708004563/isco_8k-101608.htm,0.9
10/16/2008,8-K,sec_disclosure,corporate,"X Master, Inc. invested $2,000,000 in the company and committed to invest up to an additional $1,000,000 in December 2008, subject to no adverse changes in the company prior to that date.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708004563/isco_8k-101608.htm,0.9
10/16/2008,8-K,sec_disclosure,corporate,"The company filed a press release as Exhibit 99.1 dated October 16, 2008, announcing the board election and related transaction.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708004563/isco_8k-101608.htm,0.9
9/12/2008,8-K,sec_disclosure,corporate,International Stem Cell Corporation entered into a manufacturing and supply agreement with Millipore Corporation to manufacture living cells and cell culture products for sale through Millipore’s distribution network.,https://www.sec.gov/Archives/edgar/data/1355790/000101968708004141/isco_8k-090908.htm,0.9
8/18/2008,8-K,sec_disclosure,corporate,"On August 15, 2008, the Company entered into a material definitive agreement by issuing a $350,000 Multiple Advance Convertible Note to YKA Partners, Ltd., unsecured and subordinate, bearing 8% interest per annum, convertible into common stock at $0.50 per share and due January 31, 2009.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708003755/iscc_8k-081508.htm,0.9
8/18/2008,8-K,sec_disclosure,corporate,"Concurrent with the Note, the Company granted YKA Partners, Ltd. Common Stock Purchase Warrants to acquire up to 700,000 shares at $0.50 per share, exercisable for five years and containing anti-dilution protections.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708003755/iscc_8k-081508.htm,0.9
8/18/2008,8-K,sec_disclosure,regulatory,"The Company filed a Current Report on Form 8-K with the SEC on August 15, 2008, in accordance with Sections 13 and 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708003755/iscc_8k-081508.htm,0.9
7/31/2008,8-K,sec_disclosure,corporate,"On July 30, 2008, International Stem Cell Corporation entered into subscription agreements with two accredited investors to sell 150,000 Units (each Unit comprising one share of Series B Preferred Stock and two warrants) for total proceeds of $150,000 to fund working capital.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708003314/iscc_8k-073008.htm,0.9
7/31/2008,8-K,sec_disclosure,regulatory,The sale of the Units was conducted as an unregistered private placement pursuant to exemptions under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D to accredited investors.,https://www.sec.gov/Archives/edgar/data/1355790/000101968708003314/iscc_8k-073008.htm,0.9
7/31/2008,8-K,sec_disclosure,corporate,"On May 9, 2008, the Company filed a Certificate of Designation of Rights, Preferences, Privileges and Restrictions with the Delaware Secretary of State, authorizing five million shares of Series B Preferred Stock and specifying their rights and preferences.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708003314/iscc_8k-073008.htm,0.9
6/25/2008,8-K,sec_disclosure,corporate,"International Stem Cell Corporation entered into an agreement with BioTime, Inc. and its subsidiary Embryome Sciences, Inc. to jointly produce and distribute hundreds of new standardized human and animal stem cell lines along with corresponding data and reagents.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002803/intlstem_8k-062508.htm,0.9
6/9/2008,8-K,sec_disclosure,regulatory,"Filed a Current Report on Form 8-K under Regulation FD, attaching Exhibit 99.1 (a letter to stockholders and other interested parties providing company updates and plans).",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002600/is_8k-060908.htm,0.9
5/16/2008,8-K,sec_disclosure,corporate,"On May 14, 2008, International Stem Cell Corporation entered into a Securities Purchase Agreement with an accredited investor to obtain approximately $850,000 in net proceeds in exchange for an original-issue discount senior secured convertible note and warrants.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002260/intlstem_8k-05142008.htm,0.9
5/16/2008,8-K,sec_disclosure,corporate,"The Company issued a $1,000,000 senior secured convertible note with a 15% original issue discount, due January 31, 2009, convertible into common stock at $0.50 per share.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002260/intlstem_8k-05142008.htm,0.9
5/16/2008,8-K,sec_disclosure,corporate,"Concurrent with the note, the Company issued warrants permitting the holder to purchase up to 2,000,000 shares of common stock at $0.50 per share for five years from issuance.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002260/intlstem_8k-05142008.htm,0.9
5/16/2008,8-K,sec_disclosure,ip,The convertible note is guaranteed by the Company’s subsidiaries and secured by certain patents and patent applications pursuant to Security and IP Security Agreements.,https://www.sec.gov/Archives/edgar/data/1355790/000101968708002260/intlstem_8k-05142008.htm,0.9
5/16/2008,8-K,sec_disclosure,regulatory,The convertible note and warrants were issued in an unregistered offering under applicable securities laws.,https://www.sec.gov/Archives/edgar/data/1355790/000101968708002260/intlstem_8k-05142008.htm,0.9
5/12/2008,8-K,sec_disclosure,corporate,"On May 8, 2008, the Company entered into subscription agreements with five accredited investors for the sale of 400,000 Units—each Unit consisting of one share of Series B Preferred Stock and two warrants—raising $400,000.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002109/iscc_8k-051208.htm,0.9
5/12/2008,8-K,sec_disclosure,regulatory,"On May 8, 2008, the Company sold the Units in a private placement relying on exemptions from registration under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D to accredited investors.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002109/iscc_8k-051208.htm,0.9
5/12/2008,8-K,sec_disclosure,corporate,"On May 9, 2008, the Company filed a Certificate of Designation of Rights, Preferences, Privileges and Restrictions with the Delaware Secretary of State, authorizing five million shares of Series B Preferred Stock.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708002109/iscc_8k-051208.htm,0.9
3/31/2008,8-K,sec_disclosure,regulatory,"International Stem Cell Corporation filed a Current Report on Form 8-K on March 31, 2008 pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708001394/iscc_8k-033108.htm,0.9
3/31/2008,8-K,sec_disclosure,corporate,International Stem Cell Corporation entered into an agreement with ATCC to manufacture living primary cells and cell culture products for worldwide distribution into the biological research market.,https://www.sec.gov/Archives/edgar/data/1355790/000101968708001394/iscc_8k-033108.htm,0.9
1/22/2008,8-K,sec_disclosure,corporate,"International Stem Cell Corporation announced the untimely death of its CEO, Mr. Jeff Krstich.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708000258/isc_8k-012108.htm,0.9
1/22/2008,8-K,sec_disclosure,corporate,"Kenneth C. Aldrich, the Chairman of the Board and one of the Company's founders, assumed the additional role of Chief Executive Officer, effective immediately.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708000258/isc_8k-012108.htm,0.9
1/22/2008,8-K,sec_disclosure,regulatory,"The Company filed a Current Report on Form 8-K with the Securities and Exchange Commission on January 22, 2008, including a press release as an exhibit.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708000258/isc_8k-012108.htm,0.9
1/17/2008,8-K,sec_disclosure,corporate,"On January 15, 2008, International Stem Cell Corporation entered into subscription agreements with four accredited investors, selling one million Units—each consisting of a share of Series A Preferred Stock and two warrants—raising $1.0 million in working capital.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708000233/isc_8k-011608.htm,0.9
1/17/2008,8-K,sec_disclosure,regulatory,The Units were offered and sold in a private placement transaction in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D to accredited investors.,https://www.sec.gov/Archives/edgar/data/1355790/000101968708000233/isc_8k-011608.htm,0.9
1/17/2008,8-K,sec_disclosure,corporate,"Also on January 15, 2008, the Company filed a Certificate of Designation with the Delaware Secretary of State, authorizing 5 million shares of Series A Preferred Stock and establishing their rights, preferences, privileges, and restrictions.",https://www.sec.gov/Archives/edgar/data/1355790/000101968708000233/isc_8k-011608.htm,0.9
1/14/2008,8-K,sec_disclosure,clinical,International Stem Cell Corporation announced that it will provide corneal epithelial cells derived from its parthenogenetic stem cells and human keratinocytes for use in FDA clinical trials. These trials are aimed at developing a tissue transplant technology to improve outcomes in photorefractive keratectomy (PRK).,https://www.sec.gov/Archives/edgar/data/1355790/000101968708000182/isc_8k-011408.htm,0.9
12/19/2007,8-K,sec_disclosure,corporate,"A peer-review scientific paper co-authored by Dr. Elena S. Revazova and Jeffrey Janus was published in the online edition of the Cloning and Stem Cells Journal on December 19, 2007.",https://www.sec.gov/Archives/edgar/data/1355790/000101968707004381/iscc_8k-121907.htm,0.9
12/19/2007,8-K,sec_disclosure,corporate,"The Company included as Exhibit 99.1 a press release dated December 19, 2007 in its Form 8-K filing.",https://www.sec.gov/Archives/edgar/data/1355790/000101968707004381/iscc_8k-121907.htm,0.9
9/6/2007,8-K,sec_disclosure,regulatory,"International Stem Cell Corporation filed a Form 8-K current report with the SEC on September 5, 2007, pursuant to Section 13 or 15(d) of the Securities Exchange Act to disclose other events.",https://www.sec.gov/Archives/edgar/data/1355790/000095013407019644/v33523e8vk.htm,0.9
9/6/2007,8-K,sec_disclosure,corporate,"The Company issued a press release on September 5, 2007, announcing material developments related to its research achievements.",https://www.sec.gov/Archives/edgar/data/1355790/000095013407019644/v33523e8vk.htm,0.9
9/6/2007,8-K,sec_disclosure,clinical,Data from an independent third-party laboratory confirmed that the Company successfully created tissue compatible with a human cornea from embryonic stem cells.,https://www.sec.gov/Archives/edgar/data/1355790/000095013407019644/v33523e8vk.htm,0.9
7/23/2007,8-K,sec_disclosure,corporate,"On July 19, 2007, the Board of Directors increased its size to seven members and elected Edward O. Hunter and Paul V. Maier as new directors.",https://www.sec.gov/Archives/edgar/data/1355790/000095013407015565/v32092e8vk.htm,0.9
6/28/2007,8-K,sec_disclosure,corporate,"A peer‐reviewed scientific paper co‐authored by Dr. Elena S. Revazova (Chief Scientist) and Jeffrey Janus (President) was published in the online edition of Cloning and Stem Cells Journal on June 27, 2007.",https://www.sec.gov/Archives/edgar/data/1355790/000136231007001168/c70701e8vk.htm,0.9
6/28/2007,8-K,sec_disclosure,corporate,"The Company issued a press release dated June 27, 2007, which was filed as Exhibit 99.1 to the Form 8-K.",https://www.sec.gov/Archives/edgar/data/1355790/000136231007001168/c70701e8vk.htm,0.9
3/5/2007,8-K,sec_disclosure,corporate,"On March 1, 2007, International Stem Cell Corporation’s board of directors elected Don Wright to fill a vacancy on the board and serve until the next annual meeting of stockholders.",https://www.sec.gov/Archives/edgar/data/1355790/000136231007000217/c70245e8vk.htm,0.9
3/5/2007,8-K,sec_disclosure,corporate,"On March 5, 2007, the company issued a press release announcing Don Wright’s election to the board of directors.",https://www.sec.gov/Archives/edgar/data/1355790/000136231007000217/c70245e8vk.htm,0.9
12/29/2006,8-K,sec_disclosure,corporate,"On December 28, 2006, BTHC III, Inc. entered into a Share Exchange Agreement with International Stem Cell Corporation and its shareholders, issuing 33,111,502 shares of BTHC common stock in exchange for all outstanding shares of International Stem Cell.",https://www.sec.gov/Archives/edgar/data/1355790/000136231006000442/c70133e8vk.htm,0.9
12/29/2006,8-K,sec_disclosure,corporate,"As a result of the Share Exchange, International Stem Cell became a wholly-owned subsidiary of BTHC and BTHC ceased to be a shell company under Rule 12b-2 of the Exchange Act.",https://www.sec.gov/Archives/edgar/data/1355790/000136231006000442/c70133e8vk.htm,0.9
12/29/2006,8-K,sec_disclosure,corporate,"The Share Exchange is being accounted for as a reverse merger, with International Stem Cell deemed the acquirer for accounting purposes and its historical assets and liabilities reflected on BTHC’s financial statements.",https://www.sec.gov/Archives/edgar/data/1355790/000136231006000442/c70133e8vk.htm,0.9
12/29/2006,8-K,sec_disclosure,corporate,"In connection with the Share Exchange, Kenneth Aldrich was appointed Chairman of the Board, Jeff Krstich as Chief Executive Officer, William B. Adams as Chief Financial Officer of the registrant, and Jeffrey Janus as President of BTHC and CEO of Lifeline Cell Technology.",https://www.sec.gov/Archives/edgar/data/1355790/000136231006000442/c70133e8vk.htm,0.9
12/29/2006,8-K,sec_disclosure,regulatory,"BTHC assumed registration rights to file a registration statement by February 27, 2007 to register up to 12,000,000 shares issued in a private placement, 2,400,000 warrant-underlying shares, and 1,629,623 shares underlying warrants held by International Stem Cell shareholders.",https://www.sec.gov/Archives/edgar/data/1355790/000136231006000442/c70133e8vk.htm,0.9
12/29/2006,8-K,sec_disclosure,corporate,"Former officers and directors of International Stem Cell entered into 180-day lock-up agreements restricting their ability to sell or transfer BTHC shares issued in the Share Exchange, and Halter Financial Group agreed to sell no more than one-twelfth of its holdings every 30 days.",https://www.sec.gov/Archives/edgar/data/1355790/000136231006000442/c70133e8vk.htm,0.9
11/21/2006,8-K,sec_disclosure,corporate,"On November 21, 2006, the Company completed a 4.42-for-one forward split of its common stock by way of a stock dividend to stockholders of record as of November 20, 2006. The split was approved by unanimous written consent of the Board of Directors and required no action by stockholders.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000799/bthc38k112006.txt,0.9
11/8/2006,8-K,sec_disclosure,corporate,"On November 7, 2006, BTHC III, Inc. entered into an Assignment Agreement with Bronze Marketing, Inc., Sutor Steel Technology Co., Ltd., and the Sutor stockholders to assign all the rights, obligations, and duties under the Share Exchange Agreement dated September 7, 2006.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000731/bthc38k110806.txt,0.9
9/11/2006,8-K,sec_disclosure,corporate,"On September 7, 2006, BTHC III, Inc. entered into a definitive Share Exchange Agreement with Sutor Steel Technology Co., Ltd. and its stockholders to effect a business combination under which Sutor’s shareholders will exchange all of their Sutor shares for newly issued BTHC common stock representing at least 50.1% of BTHC on a fully diluted basis upon closing.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
9/11/2006,8-K,sec_disclosure,corporate,"The Share Exchange Agreement contemplates a concurrent financing transaction expected to raise at least $25 million in gross proceeds to BTHC III, Inc. upon closing of the share exchange.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
9/11/2006,8-K,sec_disclosure,corporate,"Timothy Halter, the sole officer and director of BTHC III, Inc., agreed to resign from all offices effective at closing and from the board ten days after mailing an information statement to shareholders.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
9/11/2006,8-K,sec_disclosure,corporate,"At closing, Guoxiang Ni, currently CEO of Sutor, will be appointed as Chief Executive Officer, President, and a director of BTHC III, Inc.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
9/11/2006,8-K,sec_disclosure,regulatory,"BTHC III, Inc. agreed to file a Certificate of Completion with the United States Bankruptcy Court for the Northern District of Texas, Dallas Division, to satisfy its final obligation under its confirmed Chapter 11 plan.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
9/11/2006,8-K,sec_disclosure,regulatory,The Company must maintain its status as a quotation on the Over-the-Counter Bulletin Board and remain current in all required federal securities filings through the closing date.,https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
9/11/2006,8-K,sec_disclosure,corporate,"In connection with the share exchange, BTHC III, Inc. entered into a separate financial advisory agreement between an affiliate of its sole officer/director and an affiliate of Sutor.",https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
9/11/2006,8-K,sec_disclosure,corporate,The Company agreed to deal exclusively with Sutor regarding the contemplated business combination and to refrain from soliciting or encouraging any alternative proposals inconsistent with the Share Exchange Agreement.,https://www.sec.gov/Archives/edgar/data/1355790/000101054906000614/bthciii8k091106.txt,0.9
